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Abstract 
Photochemical internalisation (PCI) is a method for efficient delivery of 
macromolecules, like genes used in gene therapy, to the cytosol of cells. Most 
macromolecules enter a cell by endocytosis and are trapped in the endocytic vesicles. PCI is 
based on photochemical treatment disrupting the endocytic vesicles, i.e. a photosensitiser 
localised in the membranes of endocytic vesicles ruptures these vesicles upon exposure to 
light, and endocytosed macromolecules are released into the cytosol. Thus, PCI leads to an 
enhanced biological effect mediated by the liberated macromolecules.  
In the present work, this method was employed together with the non-viral vector 
polyethyleneimine (PEI) for delivery of the pro-apoptotic gene TNF-related apoptosis 
inducing ligand (TRAIL). The aim was to evaluate the potential of PCI-mediated delivery of 
the PEI/TRAIL complexes to enhance cancer cell death in vitro. Furthermore, the apoptotic 
death pathway following PCI of the TRAIL gene in colon carcinoma HCT-116 cells was 
investigated. The PCI-mediated effect was compared to the effects induced by the 
photochemical treatment alone or the treatment with the TRAIL gene alone.  
The effect of PCI was tested with respect to TRAIL expression, induction of apoptosis 
and cell survival using various methods from the fields of biochemistry and cell biology. In 
addition, the PCI effect on the level of several key molecules involved in apoptosis was 
investigated using the Western blotting technique.  
The results showed that PCI enhanced the expression and the cytotoxic effect of the 
TRAIL gene, and it also enhanced the induction of apoptosis, as compared to the other two 
treatments. It was also shown that in PCI, the TRAIL gene and the photochemical treatment 
acted additively rather than synergistically. Although the apoptotic mechanisms behind PCI of 
the TRAIL gene were not fully elucidated, there were indications that in HCT-116 cells 
apoptosis proceeds through the extrinsic (death receptor mediated) pathway, however without 
activation of the main executioner caspase, caspase-3. Moreover, photochemical up-
regulation of the TRAIL death receptor was detected. 
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Glossary 
 
o Anti-apoptotic protein – A protein that antagonises apoptosis 
 
o Apoptosis - Programmed cell death  
 
o Gene therapy - Treatment or prevention of a disease by transfer of nucleic acids 
 
o Photochemical internalisation - Delivery of macromolecules mediated by 
photochemical treatment employing photosensitisers that are localised in endocytic 
vesicles 
 
o Photochemical treatment (PDT) - Treatment with a photosensitiser followed by light 
exposure 
 
o Photosensitiser - A compound that upon light absorption induces chemical and 
physical reactions  
 
o Plasmid - A double-stranded, usually circular, DNA molecule that replicates 
independently of the genome 
 
o Pro-apoptotic protein – A protein that induces apoptosis 
 
o Promoter – A sequence to which RNA polymerase binds in order to initiate 
transcription of a gene 
 
o Reporter gene - A gene that is used to test the efficiency of gene transfection 
 
o Restriction map – A diagram showing the positions of restriction sites within a DNA 
sequence 
 
o Transfection - The process of successful gene transfer and expression 
 
o Transgene - A gene delivered into a cell by a vector 
 
o Vector - A delivery vehicle for genes or other nucleic acids 
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List of abbreviations 
 
AAV adeno-associated virus 1O2 singlet oxygen 
Adv adenovirus O.D. optical density 
AlPcS2a  aluminum phtalocyanine with two 
sulfonate groups on adjacent phenyl 
rings 
PAGE polyacrylamide gel electrophoresis 
anODN antisense oligodeoxynucleotide PARP poly (ADP) ribose polymerase 
APS ammonium persulphate PBS phosphate buffered saline 
ASPP ankyrin repeats, SH3-domain, proline 
rich region protein (ASP protein) 
PCI  photochemical internalisation 
ATCC American type culture collection PDT  photodynamic therapy 
BID Bcl-2 inhibitory domain PEI polyethylenimine 
Caspase cysteine aspartyl-specific protease PI propidium iodide 
CCD cooled charge-coupled device PI3K phosphoinositide-3 kinase 
CMV cytomegalovirus PMSF phenylmethylsulfonyl fluoride 
DAPI 4′-6-diamidino-2-phenylindole PNA peptide nucleic acid 
DcR decoy receptor PTEN phosphatase and tensin homolog on 
chromosome ten 
DD death domain PVDF polyvinylidene difluoride 
DED death effector domain RNase ribonuclease 
dH2O distilled water ROS reactive oxygen species 
DMSO dimethylsulphoxide  RPMI Roswell Park Memorial Institute 
DNA deoxyribonucleic acid  SDS sodium dodecyl sulphate 
DR death receptor siRNA small interfering RNA 
E. coli escherichia coli SMAC second mitochondria-derived activator of 
caspase 
DTT 1,4-dithio-DL-threitol tBID truncated Bcl-2 inibitory domain 
EDTA ethylenediaminetetraacetic acid TBS tris buffered saline 
EF-1α elongation factor-1α TEMED 2-Bis(dimethylamino)ethane 
EGF epidermal growth factor TGFβ transforming growth factor beta 
EGFP enhanced green fluorescent protein TNFα tumour necrosis factor alpha 
EGFR epidermal growth factor receptor TPPS2a  meso-tetra phenylporphine with two 
sulfonate groups on adjacent phenyl rings 
(LumiTrans®) 
ELISA enzyme-linked immuno-sorbent assay TRAIL tumour necrosis factor related apoptosis 
inducing ligand 
EPG2 epithelial glycoprotein-2 UV ultra violet 
EtBr ethidium bromide   
FCS  foetal calf serum   
FLIP FLICE inhibitory protein   
HEPES 4-(2-hydroxyethyl)piperazine-1-
ethanesulfonic acid 
  
HRP horseradish peroxidase   
Hsp heat shock proteins   
HSV-TK herpes simplex virus thymidine kinase   
hTERT human telomerase reverse transcriptase   
IAP inhibitor of apoptosis proteins   
LB luria bertani   
MAP mitogen-activated protein   
MTT  3-(4,5-dimethylthiazol-2-yl)-
25diphenyltetrazolium bromide 
  
NFκB nuclear factor kappa B   
Na3VO4 sodium orthovanadate   
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Introduction 
Introduction 
1  PCI – photochemical internalisation 
Macromolecules have great potential as therapeutic agents, but the potential has yet to 
be fully exploited. Therapeutic macromolecules include proteins, such as ribosome 
inactivating protein toxins for the treatment of cancer, peptides and mRNA for vaccination 
and nucleic acids like DNA (i.e. therapeutic genes), antisense oligodeoxynucleotides 
(anODN), ribozymes, peptide nucleic acids (PNAs) and small interfering RNA (siRNA) for 
gene therapy [1]. One of the major obstacles restricting the therapeutic effect of such 
macromolecules is inefficient delivery into a target cell. The majority of the macromolecules 
enter the cell by endocytosis (fig. I1) and get trapped in endocytic vesicles (endosomes and 
lysosomes) from where they are unable to escape to perform a therapeutic function. Finally, 
the trapped molecules are degraded by lysosomal enzymes [2, 3]. Therefore, endosomal 
escape is recognised to be a very important step in delivery of functional macromolecules. 
Photochemical internalisation (PCI) is a technique facilitating liberation from the endocytic 
vesicles [4]. It has been successfully applied for enhancing the effect of various 
macromolecules, both in vitro and in vivo (table I1). 
 
Figure I1 One model for the endocytic pathway from the plasma membrane to the lysosome 
(modified from [5]). Macromolecules are collected in clathrin-coated pits on the cell 
surface before endocytosis. The resulting clathrin-coated vesicles quickly lose their 
coat proteins, and the macromolecules are transported via early and late endosomes to 
the lysosome for degradation.   
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Figure I2  Schematic illustration of the principle of PCI (M = macromolecule and S = 
photosensitiser) 
. 
A) “Light after” strategy 
B) “Light first” strategy           
 
I – Uptake of macromolecules and photosensitiser via endocytosis 
II + III – Light exposure followed by rupture of the endocytic vesicles (endosomes or 
lysosomes in which the photosensitiser is localised in the membrane) and release of 
the macromolecules 
IV– Endocytic uptake of macromolecules in vesicles different from those containing 
photosensitiser 
V – Fusion between ruptured vesicles and vesicles containing macromolecules 
resulting in release of the macromolecules  
 
  C) The most widely used photosensitisers for PCI [6] 
 
A number of photosensitisers, including meso-tetraphenylporphine disulfunate 
(TPPS2a, LumiTrans®) and aluminium phtalocyanine disulfonate (AlPcS2a), bind to the plasma 
membrane and following endocytosis they are primarily localised in the membranes of 
endocytic vesicles. In combination with exposure to light, these photosensitisers induce the 
formation of reactive oxygen species (ROS), primarily singlet oxygen (1O2). 1O2 damages the 
membranes of endocytic vesicles, but does not affect the vesicular contents, including trapped 
therapeutic macromolecules, to the same extent. Therefore, functionally active 
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macromolecules can be released through the photochemically permeabilised membranes of 
the endosomes and lysosomes. This principle of delivery from endocytic compartments to the 
cytosol has been named PCI [4] and is illustrated in the figures I2 and I4. Importantly, PCI 
improves delivery and, consequently, activity of therapeutic agents only at specific, i.e. light-
exposed, areas, thereby reducing adverse effects on non target sites [1]. 
As an alternative to the PCI-procedure illustrated in figure I2A, the light may be 
delivered before administration of the macromolecule, the so-called “light first” strategy (fig. 
I2B). When “light first” is employed, permeabilised endocytic vesicles are thought to fuse 
with vesicles containing the macromolecules, and thereby releasing the endocytosed 
macromolecules into the cytosol. This alternative strategy has been successfully tested both 
for gene therapy purposes and for delivery of the protein toxin gelonin in vitro [7].  
 
Table I1  Overview of the application of the PCI-technology so far 
PCI in gene therapy approaches 
Type of 
macromolecule Examples Model systems Ref 
Gene + Adeno-
associated virus 
(AAV) 
Reporter gene Cell lines in vitro [8] 
Gene + 
Adenovirus (Adv) 
Reporter genes 
TRAIL (apoptosis inducer) 
 
Cell lines in vitro 
[7-12], 
Engesæter 
et al., 
submitted 
Gene (plasmid) + 
non-viral vectors 
Reporter genes 
p53 (apoptosis inducer) 
HSV-tk (suicide gene) 
PTEN (tumour suppressor) 
 
Cell lines in vitro 
Xenografts in vivo 
Rat eye conjunctival 
tissue in vivo 
[4, 7, 13-22]
 
siRNA targeting: S100A4 (promoter of metastasis) Cell lines in vitro Bøe et al., submitted 
Peptide nucleic 
acids (PNA) 
targeting: 
 
Reporter genes 
hTERT (involved in tumorigenesis) 
S100A4-protein (promoter of metastasis) 
 
Cell lines in vitro [23-25] 
PCI in other tumour therapy approaches 
Type of 
macromolecule Examples Model system Ref 
Chemotherapeutic 
agent Bleomycin 
Cell lines in vitro 
Xenografts in vivo [26] 
Protein toxin Gelonin (ribosome inactivating toxin) Saporin (ribosome inactivating toxin) 
Cell lines in vitro 
Xenografts in vivo 
[4, 7, 13, 27, 
28] 
Immunotoxin / 
affinity toxin 
Moc31-Gelonin (targeting EPG-2) 
EGF-Saporin (targeting EGFR) Cell lines in vitro [29-31] 
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1.1 Photochemistry and photodynamic therapy (PDT) 
The PCI technology derives from the field of photodynamic therapy (PDT) - an 
established treatment modality for several oncologic and non-oncologic indications such as 
several forms of cancer, skin actinic keratosis and age-related macular degeneration [32, 33]. 
PDT relies on three components: photosensitiser, light and oxygen. In cancer therapy, PDT is 
based on preferential uptake of photosensitiser in tumour cells followed by illumination of the 
tumour area, leading to ROS formation and, consequently, tumour destruction (fig. I3).  
Diode laser
Figure I3 Schematic illustration of the basic principle of PDT. Adapted from the front page of 
British Journal of Cancer, 57 (5), 1988     
 
Photosensitisers (S) are compounds that can be activated by light of the appropriate 
wavelength to an excited state (S*), which can further initiate photochemical/photophysical 
reactions. Usually the photochemical reactions proceed via 1O2, a highly reactive form of 
oxygen generated after interaction between an excited photosensitiser (S*) and ground-state 
molecular oxygen (O2) [34-36].  Schematically:
  
 
S  ⎯→⎯Light  S*  S + ⎯→⎯ 2O 1O2 ⇒ photochemical reactions  
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1O2 is a very powerful oxidising agent able to oxidize proteins (the amino acids, like histidine, 
tryptophan, methionine, cysteine and tyrosine), DNA (guanine), unsaturated fatty acids and 
cholesterol [37]. This leads to the damage of various cellular structures, resulting in 
cytotoxicity. Since both the lifetime (< 0.04 µs) and the range of action (< 20nm) of 1O2 are 
very short, only structures close to the photosensitiser are primarily affected [38]. Thus, the 
localisation of the photosensitiser determines which cellular organelles are directly affected 
[37], as illustrated in figure I4 for photosensitisers localised in the endocytic vesicles. 
Importantly, photochemical effect on DNA is not generally a dominant factor in PDT-
mediated cytotoxicity, and PDT usually have a low mutagenic and carcinogenic potential 
[39]. Moreover, PDT with photosensitisers localised in the endocytic vesicles, like the ones 
used in PCI, has no known mutagenic effects on chromosomal DNA [40].  
The photosensitisers used in PCI are amphiphilic molecules like AlPcS2a and TPPS2a 
(LumiTrans®) (fig. I2B) that upon endocytosis are mainly localised in the membranes of 
endocytic vesicles facing the lumen. Illumination of cells containing such photosensitisers 
induces 1O2-mediated photochemical reactions that lead to permeabilisation of the vesicular 
membranes (fig. I4). This results in release of the lysosomal content, including lysosomal 
enzymes and the photosensitisers, into the cytosol [41].  These properties of the 
photosensitisers may therefore be used to release functional endocytosed molecules, such as 
therapeutic macromolecules, from endosomes and lysosomes upon illumination (fig. I4) [4].  
Figure I4 Schematic representation (not to scale) of the main events thought to occur in the 
endocytic vesicles following photochemical treatment with the photosensitisers (S) 
like AlPcS2a and LumiTrans® used for PCI [6]. 
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Several photosensitisers with different localisation have been compared regarding 
their efficiency to induce the PCI-effect [11, 42], and it was confirmed that the localisation of 
the photosensitisers in endocytic vesicles, and especially in the endocytic membranes, is 
crucial for PCI. This indicates that endosomal release, and not the general photochemical 
effects, is responsible for the PCI-mediated enhancement of the effect of various 
macromolecules. 
1.2  PCI in cancer therapy 
Originally, PCI has been developed for use in cancer therapy approaches relying on 
macromolecules with anti-tumour activity (as illustrated in table I1). There are several reasons 
for this: 
i) Being a selective, light-dependent method PCI ensures delivery of molecules 
inducing cell death specifically to tumour cells  
ii) Photosensitisers tend to accumulate in tumour cells (as shown in fig. I3)  
iii) Photochemical treatment usually also induce cytotoxic effects (discussed in chapter 
1.1). Cytotoxicity is not desirable in situations where cells/tissues have to be 
preserved, however, in cancer therapy aiming to kill tumour cells, such cytotoxicity is 
advantageous.  
 
Therefore, PCI in combination with macromolecules triggering cell death might result in 
enhanced cytotoxicity and a synergistic anti-tumour effect. 
The “toxic” macromolecules, which are being used in combination with PCI, can 
induce cell death by direct inhibition of protein or DNA synthesis (e.g. protein toxins like 
gelonin, saporin and chemotherapeutics like bleomycin, table I1). Alternatively, cell death can 
be induced by stimulation of a death pathway or suppression of pro-survival signalling in the 
cell, shifting the balance in favour of death. There are two main death pathways, necrosis and 
apoptosis (discussed in chapter 2), and stimulation of apoptosis is one of the most exploited 
approaches in cancer therapy due to deregulated apoptosis in cancer cells (chapter 2.1.1). In 
addition, photochemical treatment (PDT) is usually highly efficient in inducing apoptosis 
(chapter 2.2) [43-48]. Therefore, combining PCI with pro-apoptotic macromolecules might 
result in enhanced apoptosis in cancer cells, and the aim of the present study was to 
investigate different aspects of such a combination, as a gene encoding an apoptosis-inducing 
protein has been employed as a pro-apoptotic macromolecule. Such a therapeutic strategy, 
 18
Introduction 
where genes or other nucleic acids are used as drugs is called gene therapy (described in 
fig. I5) and will be discussed in chapter 1.2.1.  
One of the most attractive and successful strategies for PCI is its use in gene therapy, 
facilitating the delivery of nucleic acid-based macromolecules. A number of publications have 
already demonstrated enhanced delivery, expression [8, 12-15, 18-22, 49] and therapeutic 
effect ([14-16, 19, 22] and Engesæter et al., submitted) of foreign genes (transgenes) 
following PCI. Moreover, PCI-dependent potentiation of other types of nucleic-acids, like 
PNA [23-25] and siRNA (Bøe et al., submitted) targeting proteins involved in tumorigenesis, 
has been documented. This indicates that PCI can be combined with a variety of nucleic-acid 
based macromolecules relevant for cancer therapy.  
 
1.2.1 Gene therapy 
Gene therapy (fig. I5) is the treatment of a disease by using genes or other types of 
nucleic acids as therapeutic agents with the aim to replace, alter, suppress or supplement 
genes which are defective, missing or not naturally existing in the organism [50]. Most of the 
clinical gene therapy trials to date (~ 67 %) are focused on cancer (fig. I6). Since the majority 
of cancer gene therapy protocols rely on killing cancer cells rather than on their genetic 
correction, PCI is an ideal tool for cancer gene therapy.  
 
Cytosol
Nucleus
Expressed
therap. protein
Target mRNAEndocytic
vesicles
Gene
siRNA/PNA/
ribozyme
Undesirable
target-protein 
Target cell
Therapeutic
effect
A
B
Genome
Figure I5 Illustration of the principles of gene therapy. Therapeutic nucleic acids (genes or 
siRNA/PNA/ribozymes) are delivered into a cell, usually via endocytosis. After 
liberation into the cytosol, the gene (A) is transported into the nucleus and expressed 
into a protein, which performs a desirable therapeutic function. Alternatively, 
siRNA/PNA/ribozyme (B) attack the target mRNA inhibiting the expression of an 
undesirable cellular target protein resulting in a therapeutic effect. 
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To transfer nucleic acid-based molecules into a cell, the molecules are usually packed 
into delivery vehicles, named vectors. Vectors enable delivery into target cells and their 
nuclei, provide protection from gene degradation and ensure transgene transcription in the 
cell [51]. Vectors can be divided into two groups, viral and non-viral [50, 51]. Physical 
methods for gene delivery, e.g. electroporation and gene gun are also available, and are often 
categorised among the non-viral vectors [52]. 
 
A B 
 
Figure I6 Overview of gene therapy clinical trials to date regarding indications (A) and gene 
types (B) from The Journal of Gene Medicine (www.wiley.co.uk/genmed/clinical) 
 
Viral vectors are recognised to be the most efficient gene delivery vehicles, however, 
the safety remains a major concern, as these vectors are known to trigger a host immune 
response [53]. Viral vectors are derived from natural viruses (e.g. retroviruses, adenoviruses 
(Adv), adeno-associated viruses (AAV) and others) that have innate mechanisms for efficient 
transfer of genetic material into a cell [52]. It is possible to take advantage of this, and by 
introducing a foreign gene into the virus, to deliver this gene with high efficiency into the 
target cells. Viral vectors are being developed by genetic modification of the viral genome, 
i.e. deletion of the essential viral genes (making them replication deficient) followed by the 
insertion of a therapeutic gene into the viral genome [52].   
The non-viral vectors are safer than viral, but also less efficient. A wide variety of 
non-viral vectors have been developed, including cationic polymers and cationic lipids. These 
bind to plasmid DNA carrying a foreign gene, via ionic interactions [51, 52]. The formed 
complexes, called polyplexes and lipoplexes, respectively, possess a positive net charge, 
facilitating binding to the negatively charged cell membrane and uptake into the cell by 
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endocytosis [3, 54].  The non-viral vectors can also be used for delivery of other types of 
nucleic acids like siRNA, anODN or ribozymes [51, 55]. 
A
Figure I7 The structure of PEI (A) and an illustration of its endosomolytic activity (B).  
 
Endosomal release and transport into the nucleus (fig. I5) seem to be the major 
barriers for gene therapy, especially for non-viral vectors [3, 56]. Although some cationic 
lipids and polymers (like polyethylenimine (PEI), fig. I7) have mechanisms to overcome the 
endosomal barrier, endosomolytic agents or strategies like PCI can improve the efficiency of 
such vectors [16, 18], indicating that these vectors alone are not ideal for gene delivery. 
Interestingly, the fact that the efficiency of the viral vectors like Adv and AAV can also be 
improved by PCI [8, 11],  indicate that the endosomal barrier is an obstacle even for viral 
vectors.  
In the present work PEI has been employed to deliver a pro-apoptotic transgene. PEI is 
one of the most widely used polymers for non-viral gene transfection in vitro and in vivo and 
has an advantage over other polycations in that it combines strong DNA compaction ability 
with an intrinsic endosomolytic property (illustrated in figure I7B) [57]. PEI is a cationic 
polymer with primary, secondary and tertiary amine groups, allowing for binding to DNA 
through ionic interactions at physiological pH, and the structure may be linear or branched 
(fig. I7A). Upon internalisation into endosomes via endocytic uptake [58], PEI has been 
shown to permeabilise the endosomal membrane. The proposed mechanism is that of a 
“proton sponge”, preventing the acidification of the endosomes, consequently causing vesicle 
swelling and eventual bursting (fig. I7B) [59]. 
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1.2.2 Cancer gene therapy, therapeutic principles 
Cancer gene therapy aims to eliminate, as selective as possible, cancer cells. This can 
be achieved either via immune-mediated destruction (by delivery of transgenes triggering an 
immune response to tumours) or via direct effect on tumour cells (by delivering transgenes 
triggering cell death). The latter approach will be discussed herein.  
The destruction of cancer cells can be achieved by introducing a “suicide” gene, i.e. a 
gene that encodes for (or leads to) a toxic product. “Suicide” genes have been used in ~7.5 % 
of all clinical gene therapy trials to date (fig. I6B) and the Hsv-TK (Herpes simplex virus 
thymidine kinase) is the most widely used gene. This gene encodes an enzyme, Hsv-tk, which 
converts a non-toxic product, ganciclovir, into a toxic metabolite leading to cell death [60]. 
Another alternative is the introduction of a gene or other nucleic acid-based molecules 
that affects survival and/or death-associated cellular mechanisms. The aim is to reduce pro-
survival signals and/or stimulate death signals. A very good example is to target molecules 
causing apoptosis (which was also the aim of this study). In many cancers, the mechanisms 
for activation of apoptosis are impaired (discussed in chapter 2.1.1) leading to uncontrolled 
cell growth and resistance to conventional therapies that usually relies on functional 
apoptosis [61, 62]. Therefore, the targeting of apoptosis is a promising approach in cancer 
gene therapy. This can be achieved by the delivery of: 
 
i) Genes stimulating apoptosis, such as p53 [63] or the TNF family genes like 
TRAIL [64, 65] used in the present study.  
ii) siRNA-, ribozyme- or PNA-molecules that inhibit expression of anti-apoptotic 
genes like the apoptosis-inhibitiors BCL-2, survivin or IAP (Inhibitor of Apoptosis 
Proteins) family genes [65]. 
 
Other approaches leading to suppressed tumour growth are based on the delivery of: 
 
iii) Tumour suppressor genes like PTEN which inhibits the pro-survival PI3K-Akt 
signalling pathway [19]. 
iv) siRNA, ribozyme or PNA for down-regulation of genes essential for viability, 
growth and survival of cells (e.g. the hTERT gene or genes involved in signalling 
via Ras, EGFR, TGFβ etc.) [66]. 
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1.2.3 PCI in cancer gene therapy 
Till now, PCI in gene therapy has been mostly combined with nucleic acids relevant 
for cancer therapy and has been used with most of the strategies discussed above.  
When PCI was combined with the Hsv-TK gene in vitro, increased expression of the 
toxic Hsv-tk protein was demonstrated. Moreover, enhanced cell death was observed 
following ganciclovir-administration in PCI-treated adenocarcinoma cells compared to Hsv-
TK/ganciclovir gene therapy alone [16]. 
PCI has already been used to deliver pro-apoptotic genes such as p53 and the tumour 
necrosis factor (TNF) related apoptosis inducing ligand (TRAIL). Ndoye et al. [14, 22] have 
demonstrated that PCI enhanced transfer of p53 (complexed to the nonviral PEI-based vector) 
and stimulated cell death via apoptosis both in vitro in p53-deficient carcinoma cell lines of 
the pharynx and the pancreas and in vivo in a head and neck cancer xenograft model with 
mutated p53. Engesæter et al. (submitted) have employed PCI for delivery of the TRAIL 
gene, and demonstrated significant PCI-dependent stimulation of apoptosis and activation of 
various apoptosis-related molecules in two different carcinoma cell lines in vitro. However, in 
the study of Engesæter et al., an adenoviral vector was employed for delivery of the TRAIL 
gene, while in the present work a similar PCI-based approach was studied employing the non-
viral vector PEI.    
PCI has also been used for delivery of PNA, targeting proteins associated with 
tumorigenesis. Folini et al. [24] employed PNA against hTERT (the human telomerase 
reverse transcriptase, contributing to cell growth), demonstrating marked inhibition of 
telomerase activity and reduced survival of a prostate cancer cell line in vitro. Recently, 
another study using PCI and PNA against another tumour-associated gene, S100A4, 
demonstrated PCI-induced silencing of the gene in various cancer cell lines [25].  
 
2  Apoptosis 
Apoptosis and necrosis are the main cell death pathways (fig. I8). The term 
“apoptosis” (from the Greek words apo = from and ptosis = falling in the meaning of leaves 
falling from trees or petals falling from flowers) was proposed by John F. Kerr and colleagues 
in 1972 [67]. Apoptosis is one of the main types of programmed cell death (although the term 
“programmed cell death” also covers processes like mitotic catastrophe, caspase-independent 
cell death and autophagy [68]). Apoptosis is an active and controlled process executed by 
cysteine aspartyl-specific proteases (caspases). It is different from another main death form, 
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necrosis, which is an un-programmed and accidental cell death in which caspases are not 
involved. In necrosis the cells suffer a major insult, leading to loss of membrane integrity, 
swelling and disruption of the cells and subsequent inflammation (fig. I8) [69]. 
Apoptosis is characterized by distinct morphological changes, hallmarks of apoptosis. 
These include condensation and fragmentation of nuclear chromatin, loss of mitochondrial 
membrane potential, cleaveage of caspase targets, cell shrinkage and alterations of the plasma 
membrane finally resulting in the phagocytosis of apoptotic cells. Phagocytosis subsequently 
prevents an inflammatory response and neighbouring cells remain unaffected [70]. It is 
generally accepted that executioner caspases are responsible for the apoptotic hallmarks.  
 
Figure I8 Illustration of the main cell death pathways [71]. 
 
Apoptosis is involved in many important cellular processes, including normal cell 
turnover, the immune system and embryonic development [65]. Apoptosis is also evident in 
cells exposed to stressful stimuli or damage, thereby preventing the maintenance and 
proliferation of potentially dangerous cells. Inappropriate apoptosis, leading to either 
increased or reduced cell death, has been implicated in many human diseases including cancer 
[65, 70].  
2.1 Apoptosis pathways  
There are two main signalling pathways that initiate the apoptotic suicide program in 
mammalian cells: the extrinsic (mediated by death receptors (DR) on the cell surface) and the 
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intrinsic (mediated by mitochondria) pathways (fig. I9). Both pathways involve caspases, but 
differ in the way the death signal is transduced. 
Extrinsic pathwayIntrinsic (mitochondrial ) pathway
TNF-family ligands
DR
Cleavage of death substrates and apoptotic death 
  
Figure I9 Simplified illustration of the main signalling pathways of apoptosis (modified from 
[72]) 
 
The extrinsic pathway is initiated by the members of the TNF-superfamily, like TNFα, 
FAS-ligand and TRAIL. Binding of such ligands to their respective receptors (DR) results in 
aggregation (trimerisation) of the receptor and clustering of the intracellular death domains 
(DD) (fig. I9).  This leads to the recruitment of the adaptor protein FADD and the subsequent 
binding (via the death-effector domain (DED)) and cleavage of inactive procaspase-8 (an 
initiator caspase which is activated by cleavage). Activated caspase-8 will then cleave 
caspase-3, -6, and 7 (executioner caspases, caspase-3 being the most important), leading to 
cleavage of the death substrates such as structural and regulatory proteins like lamins, 
cytokeratins and poly (ADP-ribose) polymerase (PARP) [69, 72]. 
The intrinsic pathway is triggered as a response to DNA damage, cell cycle checkpoint 
defects, hypoxia, loss of survival factors or other types of severe cell stress including PDT 
(discussed below in chapter 2.2). This pathway involves activation of the pro-apoptotic arm of 
the Bcl-2 gene superfamily, which in turn engages the mitochondria to cause the release of 
apoptogenic factors such as cytochrome c and SMAC into the cytosol (fig. I9). Cytochrome c 
subsequently binds the adaptor protein APAF-1, forming an “apoptosome” that activates 
caspase-9 (initiator caspase) leading to activation of the executioner caspases-3, 6 and 7. 
SMAC promotes apoptosis by binding to inhibitor of apoptosis proteins (IAP), thereby 
preventing these factors from attenuating caspase activation (fig. I9) [69, 72]. 
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The two signalling pathways also communicate with each other; caspase-8 activated 
by the extrinsic pathway can cleave the pro-apoptotic Bcl-2 family member Bid to its active 
form tBid, promoting cytochrome c release from the mitochondria and activation of the 
intrinsic pathway (fig. I9). Caspase-8 mediated Bid-processing thereby provides a bridge 
between the two pathways, causing an amplification of the extrinsic signal and a subsequent 
augmentation of apoptotic cell death [69].   
Two different cell types have been described with respect to apoptotic mechanisms. In 
type I cells, caspase-8 activation via the extrinsic pathway is sufficient to kill cells. In type II 
cells (like the HCT-116 cells [73] used in the present study) however, cell death is dependent 
on amplification of the signal via activation of the intrinsic pathway [74, 75]. 
 
2.1.1 Apoptosis in cancer 
Table I2  Mechanisms of resistance to apoptosis, potential targets for cancer therapies (modified 
from [76] and [77]) 
Pathways and molecules involved in resistance to apoptosis 
Expression of anti-apoptotic molecules Down-regulation and mutation of pro-apoptotic genes  
Anti-apoptotic BCL2 family members (BCL2, 
BCL-XL,) – inhibit apoptosis at the 
mitochondria level (fig. I9) 
BAX – involved in mitochondrial apoptosis (figs.  I9, I11) 
FLIP - prevents apoptosis through death 
receptors  
APAF1-binds released cytochrome c  (figs.  I9, I11) 
Soluble receptors (sCD95, DcR) - act as decoys 
for death ligands (figs. I9, I10) 
Caspase-8 - executioner caspase (figs. I9, I11) 
IAP family (survivin, cIAP2, XIAP)- inhibit 
caspases (fig. I9) 
Death receptors (CD95, DR4, DR5) (fig. I9) 
Deficiency in the apoptotic p53 pathway Stimulation of survival signalling via the PI3/AKT pathway 
 ↓ p53 – central in apoptosis  ↑ PI3K  
 ↓ PTEN  (tumour supressor) 
↓ ASPP – stimulates p53 function ↑ AKT  
Other mechanisms 
Activation of NF-kB (chapter 2.2.1) 
 Induction of heat shock proteins (Hsp) (chapter 2.2.1) 
In many cancers, the normal process of eliminating unwanted cells (i.e. apoptosis) is 
deregulated. Tumour cells acquire resistance to apoptosis by down-regulation or mutation of 
pro-apoptotic genes and/or by the increased expression of anti-apoptotic genes (table I2) [61, 
76].  Therefore, apoptosis can be restored or triggered by cancer gene therapy approaches 
targeting the defects in apoptosis signalling as already discussed in chapters 1.2.2 and 1.2.3.  
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2.2 PDT and apoptosis 
Although PDT can lead to apoptosis or necrosis, or a combination of these two 
mechanisms, PDT is highly efficient in inducing apoptosis in many cases [45]. It appears as if 
low doses of PDT favour apoptosis, while high doses favour necrosis [45, 78]. The efficiency 
of PDT as an inducer of apoptosis depends on the cells, the treatment conditions, and, 
particularly, on the photosensitiser and its subcellular localisation, as has been demonstrated 
both in vitro and in vivo [43-48, 79]. Generally, photosensitisers that are localised in the 
mitochondria are the most efficient for induction of apoptosis following PDT [48]. However, 
photosensitisers that are localised in lysosomes, like the ones used in PCI, have also been 
shown to initiate the apoptotic death program [48, 79]. The kinetics of apoptosis induction 
seems also to depend on the localisation of the photosensitiser. Noodt et al. [48] showed that 
the mitochondria-localised photosensitisers induce rapid (within a few hours) apoptosis, while 
lysosomal photosensitisers like the PCI-relevant LumiTrans® or TPPS4, induce late apoptosis 
(more than 12 h after PDT). This indicates that there is no universal mechanism for the 
apoptotic signalling following PDT. 
Usually, PDT initiates the intrinsic (mitochondrial) apoptotic pathway (fig. I10) 
whereas the role of the extrinsic pathway following PDT is controversial [45]. Recent studies 
indicate that disruption of lysosomes releases lysosomally located cathepsins to the cytosol, 
where they cleave Bid leading to apoptosis via the intrinsic pathway (fig. I10) [80, 81]. Since 
the photosensitisers used in PCI mediate lysosomal/endosomal damage, it is likely that PCI 
treatment will function similarly, i.e via the intrinsic pathway.  
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Figure I10 Major molecular events leading to apoptosis following PDT with differently localised 
photosensitisers [45] 
 
2.2.1 PDT and pro-survival signalling 
It has been shown that PDT can also induce anti-apoptotic signals, e.g. activate the 
transcription factor nuclear factor–kappa B (NF-κB) [78, 82] or induce heat-shock proteins 
(Hsp) [83]. NF-κB often acts as a survival factor and can prevent apoptosis by up-regulation 
of anti-apoptotic genes like IAP (fig. I9) [82, 84]. HCT-116 cells (also used in this study) 
have been used to show that photochemical activation of NF-κB might partially protect from 
apoptosis initiated by PDT with photosensitisers localised in membranes and lysosomes [78].  
In addition, photochemical induction of heat shock proteins like Hsp-70 might also counteract 
apoptosis [85]. Hsp prevent apoptosis by direct interaction with different key apoptotic 
proteins, e.g. Hsp70 bind directly to Apaf-1, thereby preventing the recruitment of 
procaspase-9 and subsequent activation of procaspase-3 (figs. I9 and I10) [86-90]. Lately it 
has been shown that the PCI-relevant PDT treatment also induces Hsp-70 [83],  indicating 
that both apoptotic and anti-apoptotic signals might be initiated by photochemical treatment.  
2.3 Tumour necrosis factor (TNF) related apoptosis inducing ligand                    
(TRAIL) 
Employment of TRAIL in order to promote apoptosis (extrinsic pathway) is a 
promising approach currently undergoing preclinical and early clinical studies for various 
malignancies [72, 91]. TRAIL is especially attractive due to its ability to induce apoptosis in 
tumour cells of diverse origin, with little toxicity toward normal cells [92, 93]. Although the 
 28
Introduction 
TRAIL protein initially seemed to be an ideal molecule for achieving a selective and powerful 
anti-tumour effect, there are limitations to its clinical use, e.g. instability of the TRAIL protein 
and the toxicity observed in non-malignant liver cells with some recombinant forms of the 
protein [94, 95]. Thus, TRAIL gene therapy has been proposed as a way of achieving high 
intra-tumoral concentrations of TRAIL for a sustained period of time, and this strategy has 
been used in the present study. 
 TRAIL is a type II transmembrane protein, exposing its c-terminal domain into the 
extracellular space [92, 96], and inducing apoptosis through interaction with its death 
receptors, DR4 and DR5. Though five human receptors for TRAIL have been identified – the 
death receptors DR4 and DR5, the decoy receptors DcR1 and DcR2 and a soluble receptor 
osteoprotegrin (OPG) - only DR4 and DR5 contain functional death domains (DD) (fig. I11) 
able to signal apoptosis via the extrinsic pathway (fig. I9). The other three receptors bind to 
TRAIL but do not have functional DD (fig. I11), therefore do not initiate apoptosis and may 
infer resistance to TRAIL-mediated apoptosis by competing with DR4 and DR5 [97].  
 
 Figure I11 TRAIL and its receptors [74].  
 
In addition to induction of apoptosis, TRAIL binding to its receptor may also lead to 
activation of the transcription factor NF-κB, which can prevent apoptosis by stimulation of 
anti-apoptotic genes e.g. IAP (table I2, fig. I9). Therefore, in many cells, TNF/TRAIL 
negatively regulates its own cytotoxicity by NF-κB activation [98]. 
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Normal cells are generally resistant to TRAIL, which is advantageous in respect to 
cancer therapy. However, lately it has also been reported that some tumour cells might be, or 
might become, resistant to TRAIL treatment [77, 99]. Various factors could contribute to such 
resistance e.g. over expression of DcRs (a mechanism proposed for normal cells) and 
apoptosis inhibitors (IAP), activation of NF-κB and MAP kinases, [77, 100] low expression 
level of the DRs [101], and elevated levels of heat shock proteins like Hsp-70 [86]. 
Accumulating evidence suggest that a combination of TRAIL gene therapy with e.g. 
chemotherapy or radiotherapy may overcome such resistance [102-106].  Moreover, it has 
been demonstrated that the combination of TRAIL-therapy with PDT (based on other 
photosensitisers than those used in PCI) can also augment induction of apoptosis [107]. 
Combination therapies might sensitise cells to TRAIL by various mechanisms:  
 
i) Up-regulation of pro-apoptotic molecules like DRs [108]  
ii) Stimulation of caspase-3 and caspase-8 [108]  
iii) Activation of the mitochondrial (intrinsic) pathway [107]  
iv) Down-regulation of apoptosis inhibitors like c-FLIP [103, 104]   
v) Suppression of the NF-κB pathway [100, 109] 
 
Hence, it seems that combining TRAIL gene therapy with other therapeutic 
approaches will play a major role in TRAIL-based therapies in the future. In this respect, the 
photochemical treatment initiating PCI may be reckoned as a form of PDT, and therefore it 
was of interest to study whether this photochemical stimulus could enhance TRAIL mediated 
apoptosis in our experimental system.  
 
 
 
 30
Introduction 
Aim of the study  
The overall aim of the present study was to evaluate the potential of PCI-mediated 
delivery of a therapeutically relevant gene, the pro-apoptotic gene TRAIL, carried by the 
nonviral vector polyethylenimine (PEI) to enhance cancer cell death in vitro. Furthermore, to 
investigate the apoptotic death pathway following PCI-mediated transfection of the TRAIL 
gene in colon carcinoma HCT-116 cells.  
In this regard, the partial aims were: 
i) To evaluate PCI of the PEI/TRAIL polyplexes in respect to: 
- Reduction of cell survival 
- Induction of apoptosis 
- Effect on different apoptosis-related proteins. 
ii) To compare the effect of PCI-mediated TRAIL gene transfection with the effects achieved 
by photochemical treatment (PDT) alone or TRAIL gene transfection  alone.    
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Materials and methods 
1 Materials  
1.1 Reagents 
 
Table M1 List of reagents 
Reagent name Origin 
Acrylamide/Bis Bio-Rad Laboratories (Hercular, CA, USA) 
Agarose SIGMA-Aldrich (St Louis, MO, USA) 
Amersham ECL plusTM Western Blotting 
detection reagents 
GE Healthcare (Little Chalfont, Buckinghamshire, 
UK) 
Ampicillin SIGMA-Aldrich 
APS Bio-Rad Laboratories 
Benzonase Merck (Darmstadt, Germany) 
β-glycerolphosfate Fluka Chemie AG (Buchs, Switzerland) 
Biotinylated Protein Ladder Detection Pack Cell Signaling Technology (Beverly, MA, USA) 
DC protein assay kit II Bio-Rad Laboratories 
DMSO SIGMA-Aldrich 
DTT Fluka Chemie AG  
EDTA SIGMA-Aldrich 
Enz-check Caspase-3 assay kit #2 Molecular Probes (Eugene, OR, USA) 
EtBr SIGMA-Aldrich 
FCS PAA laboratories Gmbh  (Pasching, Austria) 
Glutamin SIGMA-Aldrich 
Glycerol BDH Laboratory supplies (Poole, UK) 
HEPES SIGMA-Aldrich 
HRP-labelled anti-goat secondary antibody Serotec (Oxford, UK) 
HRP-labelled anti-mouse secondary antibody GE Healthcare 
HRP-labelled anti-rabbit secondary antibody Promega (Madison, USA) 
Human TRAIL ELISA kit Biosource (Camarillo, CA, USA) 
Kanamycin SIGMA-Aldrich 
LB-Agar Bio 101 (Carlsbad, CA, USA) 
LB medium Bio 101  
LumiTrans® PCI Biotech AS (Oslo, Norway) 
MTT SIGMA-Aldrich 
Na3VO4 SIGMA-Aldrich 
Na-deoxycholic acid SIGMA-Aldrich 
PBS SIGMA-Aldrich 
pEGFP-N1 (plasmid encoding EGFP) Clontech Laboratories (Palo Alto, CA, USA) 
pEGFP-TRAIL (plasmid encoding the EGFP-
TRAIL fusion protein) 
Kind gift from Prof. B. Fang (The University of 
Texas, TX, USA) 
PEI 22 kDa, linear Kind gift from Prof. E. Wagner (Ludwig-
Maximilians University, Munich, Germany) 
Penicillin/Streptamycin solution SIGMA-Aldrich 
Phosfatase inhibitor cocktails I and II SIGMA-Aldrich 
PI  SIGMA-Aldrich 
 32
Materials and methods 
Reagent name Origin 
Plasmid midi-prep purification kit Qiagen Gmbh (Hilden, Germany) 
PMSF Fluka Chemie AG 
Ponceau S SIGMA-Aldrich 
pORF-hTRAIL (plasmid encoding the TRAIL 
protein) 
Invivogen (San Diego, CA, USA) 
Powdered skimmed milk Nestlé food service (Vevey, Switzerland) 
Primary antibodies against caspase-3, caspase-
8 and caspase-9 (mouse monoclonal) 
Cell Signaling Technology 
Primary antibody against α-tubulin (mouse 
monoclonal) 
Calbiochem (San Diego, CA, USA) 
Primary antibody against DR5 (goat 
polyclonal) 
Santa Cruz Biotechnology (Santa Cruz, CA, USA) 
Primary antibody against PARP (rabbit serum) Calbiochem  
Protease inhibitor coctail SIGMA-Aldrich 
Protein Standards KaleidoscopeTM Bio-Rad Laboratories 
Restriction enzymes (NotI, NheI, NcoI, 
EcoRI) 
New England Biolabs (Beverly, MO, USA) 
RPMI 1640 cell medium SIGMA-Aldrich 
SDS Bio-Rad Laboratories 
TEMED Bio-Rad Laboratories 
Tergitol NP-40 SIGMA-Aldrich 
Tris-Base Bio-Rad Laboratories 
Trypsin-EDTA SIGMA-Aldrich 
 
1.2 Cell lines and bacteria 
The human colon carcinoma cell lines HCT-116 (catalogue no CCL-247) and WiDr 
(catalogue no CCL-218) were from ATCC (Rockville, MD, USA). 
SoloPack® gold Competent E-coli cells (XL-10 gold strain) were from Stratagene (La Jolla, 
CA, USA) 
2 Methods 
2.1 General cell treatment 
2.1.1 Cell culture 
HCT-116 and WiDr cells were subcultured twice a week in RPMI 1640 medium 
supplemented with 10 % foetal calf serum (FCS), 100 U/ml penicillin, 100 µg/ml 
streptomycin and 2 mM glutamine (complete growth medium) at 37oC in a humidified 
atmosphere containing 5 % CO2. The cells were routinely kept between passage 4 and 30, and 
they were tested regularly for mycoplasma infection.  
When seeded out for experiments, the cells were detached by trypsinisation, pelleted 
(180 xg for 3 min with a table centrifuge (Beckman Coulter, Fullerton, CA, USA)) and 
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resuspended in complete growth medium. The amount of cells in the suspension was counted 
by using a “glasstic®slide 10 with grids” (Hycor Biomedical Inc., Garden Grove, CA, USA) 
and the appropriate amount of cells (table M2) was seeded out for experiments.  
 
2.1.2 PCI-procedure 
To induce PCI, the photosensitiser LumiTrans®, (meso-tetraphenylporphine with two 
sulfonate groups on adjacent phenyl rings, TPPS2a) was used. The absorbtion spectrum of the 
photosensitiser is shown in figure M1A. 
For PCI-based gene transfection with the “light after” strategy (described in fig. 
M2A), cells were seeded out (as described in table M2) 6 h prior to addition of LumiTrans® 
(0.4 µg/ml). After incubation over night, the cells were washed 3x to remove any excess of 
the photosensitiser before the addition of the PEI/plasmid DNA polyplexes.   
The polyplexes at N/P ratio 4 (N/P = molar ratio of PEI nitrogen to DNA phosphate) 
were prepared by mixing plasmid and PEI solutions prepared separately. Per ml of 
transfection medium: 5 µg of plasmid DNA and 26 µl of PEI solution (0.1 mg/ml) was each 
diluted in 20 mM HEPES buffer (pH 7.2) to a working volume of 50 µl. The PEI-mix was 
added to the DNA-mix (a pipette was used for gentle mixing) and the solution was incubated 
in room temperature for 20 min. The polyplex solution was diluted with complete growth 
medium to 1 ml (final plasmid concentration 5 µg/ml) or 2 ml (final plasmid concentration 
2.5 µg/ml), and the appropriate volume for transfection (indicated in table M2) was added to 
the cells.  
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Figure M1 The absorbtion spectrum of LumiTrans® (A) and the emission spectrum of the 
LumiSource® lamp.  
 
 34
Materials and methods 
After 4 h of incubation allowing for endocytosis of the polyplexes, the cells were 
washed once (to remove polyplexes that were not endocytosed) and exposed to light from the 
LumiSource® lamp (PCI Biotech AS, Olso, Norway). The LumiSource®, which is designed 
for excitation of the LumiTrans®, emits light from four light tubes of λ = 375-450 nm with a 
peak at 435 nm (fig. M1B) and has a fluence rate of 8.5 W/m2.  
Over night incubation
Wash 3x
4 hours incubation
Wash 1x
Polyplex Fresh mediumLumiTrans®
Light
Figure M2  Outline of a standard PCI-based gene transfection (“light after” strategy) with 
non-viral vectors 
 
For PCI-based gene transfection with the “light first” strategy (described in fig. M2B), 
cells were also seeded out (as described in table M2) 6 h prior to addition of LumiTrans® 
(0.4 µg/ml). After incubation over night, the cells were washed 3x to remove any excess of 
the photosensitiser before 4 h of incubation followed by exposure to light from the 
LumiSource® (fig. M2B) and subsequent addition of the PEI/plasmid DNA polyplexes as 
described above. The cells were incubated for 4 h before they were washed once to remove 
excess polyplexes.   
The cells were finally analysed for various parameters at different time points after 
light exposure. Control “no PCI” cells were treated identically except that light was not 
applied, and control “PDT” cells were exposed to the photochemical treatment without 
polyplexes.  
To pellet the cells for further analysis, centrifugation was performed at 1100 xg or 
2200 xg (depending on the rotor) for ~30 s by using the table centrifuge from Beckman 
Coulter. 
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Table M2  Conditions for experimental cell culture 
Type of experiment Type of plate, dish or flask* 
Total amount of 
cells seeded out 
Volume of 
medium during 
incubation 
Volume of 
medium during 
transfection 
SubG1-assay and 
EGFP flow 
cytometry 
12-well plate 80 000 1 ml 0.45 ml 
Hoechst staining and 
EGFP fluorescence 
microscopy  
6-well plates 160 000 2 ml 0.6 ml 
Western blotting Falcon 3003-dish 1 300 000 7 ml 5 ml 
Caspase3 enzymatic 
assay and TRAIL 
ELISA assay 
25 cm2 flask 400 000 5 ml 1.5 ml 
MTT-assay 
MTT-assays were usually done in parallel with the other experiments and 
therefore in the same type of plate or dish.  However, when the 25 cm2-flasks 
were used, the MTT-assay was carried out in 6-well plates. 
*Flasks and plates were from Nunc (Roskilde, Denmark), dishes from Becton Dickinson Labware (Franklin 
Lakes, NJ, USA) 
 
2.2 Production and purification of the plasmids pORF-hTRAIL and 
pEGFP-TRAIL 
SoloPack Gold competent E. coli cells were transformed with the plasmid according to 
the manufacturer’s instructions. Briefly, 10-50 ng plasmid DNA was added to the competent 
cells, and the cells were heat-pulsed at 42oC for 60 s. After 1 h incubation at 37oC, the 
transformed cells were selected on LB-agar plates containing 50 µg/ml of either ampicillin 
(for pORF-hTRAIL) or kanamycin  (for pEGFP-TRAIL). Transformed bacterial cells were 
kept as glycerol stocks (1:1) at –80oC.  
To produce the plasmids, transformed bacterial cells were grown overnight in LB-
medium containing the appropriate antibiotics. The resulting biomass was centrifuged, and 
the plasmids were isolated from the bacterial pellet by using the midi-prep plasmid 
purification kit according to the manufacturer’s instructions. The plasmid concentration was 
calculated by measuring optical density (O.D.) of the plasmid solution in a quartz cuvette 
(100 µl, 1 cm light path) at 260 nm using the ultrospec 2100 pro UV/Visible 
spectrophotometer (Amersham Biosciences).  
The quality of the produced plasmids was verified by digestion with restriction 
enzymes (fig. M3 shows the plasmid restriction maps) followed by separation of the DNA 
fragments on a 0.8 % agarose gel (run at 80 V for 30 min). λ DNA-Hind III digest was used as the 
size marker.  The DNA fragments were visualized by staining the gel with EtBr (0.5 µg/ml) 
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followed by exposure to UV-light. Images were obtained by the DC40/DC120 camera and the 
1D Image analysis software from Kodak (Rochester, NY, USA).  
Finally, the stock solution obtained was diluted to approximately 1 mg/ml and sterile 
filtered through a 0.22 µm pore filter (Corning Inc., Acton, MA, USA). 
 
Figure M3  Restriction maps of the plasmids produced in this study (supplied from Invivogen 
(pORF-hTRAIL) and Prof. B. Fang (pEGFP-TRAIL)).  
CMV 
NheI (592) 
Not I 
(2247) 
2.3 Evaluation of transgene expression 
In the present work expression of the reporter (EGFP) and the therapeutic (TRAIL) 
transgenes were evaluated. The EGFP transgene encodes a fluorescent protein, which was 
detected by fluorescence microscopy (described in chapter 2.3.1) and flow cytometry 
(described in chapter 2.3.2) as a marker for transfection efficiency. Expression of the 
therapeutic TRAIL transgene was evaluated by a quantitative sandwich enzyme immunoassay 
(described in chapter 2.3.3).  
  
2.3.1 Analysis of EGFP transgene expression by fluorescence microscopy 
EGFP-positive cells can be identified by fluorescence microscopy, which allows to see 
the intracellular localisation of the EGFP protein as well as the distribution of the EGFP-
positive cells in the whole cell population.  
HCT-116 cells were transfected with the pEGFP-N1 plasmid and exposed to light 
(PCI) or kept in the dark (“No PCI”). Two days later, the cells were observed by a Zeiss 
(Oberkochen, Germany) Axioplan fluorescence and phase-contrast microscope equipped with 
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a 20x-magnification air objective. An HBO/100W mercury lamp was used for excitation. To 
detect EGFP, a 450-490 nm band pass excitation filter, a 510 nm dichroic beam splitter and 
510-540 nm long pass emission filter were used. Micrographs were recorded by means of a 
cooled charge-coupled device (CCD) camera (Photometrics Inc., Tucson, AZ) and analysed 
with the AnalySIS^D 5.0 software (Olympus Biosystems Gmbh, Hamburg, Germany). 
 
2.3.2 Analysis of EGFP transgene expression by flow cytometry 
In flow cytometry, single cells are analysed for fluorescence. Therefore, the 
percentage of cells expressing EGFP from a large cell population can be quantified.  
HCT-116 cells were treated according to the PCI procedure described in chapter 2.1.2 
and harvested by trypsinisation 24, 48 or 72 h after light exposure. After centrifugation, the 
cells were resuspended in 400 µl complete growth medium and filtered through a 50 µm-pore 
mesh nylon filter to remove cell aggregates. To discriminate between viable and dead cells, 
1 µl of PI (0.5 mg/ml stock), which stains only dead cells, was added, and the cells were 
analysed by means of a FACS Calibur flow cytometer (Becton Dickinson, San Jose, CA, 
USA) measuring EGFP fluorescence through a 510-530 nm filter and PI fluorescence through 
a 655-669 nm filter after excitation with an argon laser at 488 nm. For each sample 10 000 
events were collected. Dead cells were discriminated from viable cells by gating on the PI 
fluorescence signal. Cell doublets were discriminated from single cells by gating on PI pulse 
width versus pulse area. The data were analysed with the CELLQuest software (Becton 
Dickinson). 
An MTT-assay (described in chapter 2.5.1) was performed in parallel to evaluate the 
effect of the treatment on cell survival. 
  
2.3.3 Analysis of TRAIL transgene expression by an ELISA assay 
The level of the TRAIL protein expressed from the pORF-hTRAIL plasmid was 
measured in both growth medium and cell lysates by using the Human TRAIL ELISA kit 
based on a biotinylated anti-hTRAIL antibody in combination with a streptavidin-horse radish 
peroxidase (HRP) conjugate and a substrate for HRP. HRP-generated yellow colour develops 
in proportion to the amount of TRAIL. 
HCT-116 cells were treated as described in chapter 2.1.2. At 24 h after light exposure, 
the medium with floating cells was collected and centrifuged to pellet the floating cells and to 
separate the cells from the growth medium (supernatant). The supernatant was stored at -80oC 
until analysis. The adherent cells were scraped in PBS by means of a rubber policeman 
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(Corning) and combined with the pelleted cells. After wash with PBS, the cells were lysed in 
a lysis buffer provided with the kit, and the cell lysates were also stored at - 80oC.  
The amount of TRAIL in each sample was determined in both cell lysate and 
supernatant (medium) using the according to the manufacturer’s instructions. Briefly, the 
lysate/supernatant were transferred to anti-hTRAIL-coated microplate wells and after 2 h 
incubation and wash, biotin-conjugated anti-hTRAIL was added for further 1 h incubation. 
After wash, a streptavidin-HRP-conjugate was added followed by wash and addition of a 
“chromogen” solution, which is a substrate for HRP. Yellow colour was subsequently formed, 
which was detected at 450nm using a microplate reader (Victor2 1420 multilabel counter from 
Perkin Elmer, (Wellesley, MA, USA)) measuring fluorescence, absorbance and luminescence. 
The intensity of the colour is proportional to the amount of TRAIL bound in the initial step 
and, therefore, reflects the amount of TRAIL in a sample. The amount of expressed TRAIL in 
each sample was quantified from a standard curve based on O.D. measurements of the known 
amounts of the TRAIL-protein provided as a standard. The amount of expressed TRAIL was 
normalised to the total protein amount in each sample. The total amount of protein in the cell 
lysates was determined as described in chapter 2.5.2.  
2.4 Methods for detection of apoptotic cells 
Apoptosis was measured using three different approaches; cells were stained with 
Hoechst 33342 for visualisation of apoptotic nuclei, the level of active caspase-3 was 
measured and flow cytometric measurements of DNA-content were performed. 
 
2.4.1 Hoechst staining  
The Hoechst 33342 dye stains DNA in living cells and can be used to visualise 
(microscopically) normal cells, where DNA is distributed in an even and diffuse pattern 
throughout the nucleus, and apoptotic cells, where DNA is fragmentary and concentrated in 
strongly fluorescent granules.  
HCT-116 cells were treated as described in chapter 2.1.2 and analysed 24 and 48 h 
after light exposure. Hoechst 33342 (10 µl of 0.562 mg/ml stock) was added to the medium, 
and after 5 min the cells were observed by an inverted Zeiss microscope, Axiovert 200 
equipped with air-objectives (20x magnification) and a filter for DAPI (365/12 nm band pass 
excitation filter, a 395 nm beam splitter, and a 397 nm long pass emission filter). Pictures 
were composed by the use of Carl Zeiss AxioCam HR, Version 5.05.10 and AxioVision 
3.1.2.1 software. Pictures were processed in AnalySIS^D 5.0 software.  
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2.4.2 Caspase-3 enzymatic assay 
Activation of caspase-3 indicates caspase-dependent apoptosis, as this is the main 
executioner caspase (see introduction, chapter 2). Caspase-3 activity was measured by the 
EnzCheck Caspase-3 Assay kit #2 based on a caspase-substrate coupled to rhodamine 110, 
which starts fluorescing when cleaved by active caspase-3.  
HCT-116 or WiDr cells were treated as described in chapter 2.1.2. Both floating and 
adherent cells were harvested 6, 18, or 48 h (for HCT-116) and 18 h (for WiDr) after light 
exposure. The pelleted cells were washed once with PBS and stored at –80oC before further 
analysis. Caspase-3 activity was determined according to the instructions of the kit 
manufacturer. Briefly, the cells were lysed during one freeze-thaw-cycle and the cell lysates 
of each sample were added to the microplate wells followed by addition of the enzymatic 
substrate. After incubation at room temperature for ~ 40 min, the samples were analysed for 
rhodamine 110 fluorescence using the fluorescein settings (excitation filter 485 nm, emission 
filter 535 nm, 1.0 s measurement time) in the Victor2 1420 multilabel counter.  
An MTT assay (chapter 2.5.1) and a protein assay (chapter 2.5.2) were performed in 
parallel to be able to relate the fluorescence (representing caspase-3 activity) to cell survival 
and to the amount of total protein in the cell lysates, respectively.  
 
2.4.3 SubG1-assay 
The SubG1-assay is based on the fact that apoptotic cells lose part of their DNA due to 
the DNA fragmentation during apoptosis. Those cells may be detected as a “Sub-G1” 
population because they have less DNA than a normal cell in the G1 cell cycle phase. 
Staining DNA of fixed cells with PI allows for distinguishing between normal cells (with 
normal DNA content) and apoptotic cells (with reduced DNA content) by analysing PI 
fluorescence intensity histograms [110].  
HCT-116 cells were treated as described in 2.1.2 and both floating and adherent cell 
were harvested 24, 48 or 72 h after light exposure. The pelleted cells were fixed in 500 µl of 
ice-cold 100% methanol and kept at -20oC at least overnight. Before analysis, the fixed cells 
were pelleted, washed once with warm (37oC) PBS and resuspended in warm PBS containing 
RNaseA (100 µg/ml) to remove RNA, which would interfere with PI-staining of DNA. After 
30 min incubation at 37oC, the cells were filtered as described in chapter 2.3.2. To stain DNA, 
1 µg/ml of PI was added and the DNA content was analysed by the FACS Calibur flow 
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cytometer, measuring PI fluorescence through a 655-669 filter after excitation with an argon 
laser at 488 nm. For each sample 5000 – 20 000 events were collected. PI fluorescence pulse 
area was used as a measure of DNA content. Cell doublets were discriminated by gating on PI 
pulse width versus pulse area. The data were analysed with the CELLQuest software.  
2.5 Measurements of cell viability and protein/DNA content 
2.5.1 MTT-assay 
3-[4.5-dimetylthiazol-2-y]-2.5 difenyltetrazolium bromide (MTT) is a substrate for 
mitochondrial dehydrogenases resulting in the formation of formazan crystals of purple 
colour. The intensity of the colour is assumed to be proportional to the number of viable 
cells[111]. It should, however, be noted that the MTT-results may be influenced by cell 
proliferation, i.e. viable cells will divide and subsequently constitute an increasingly large 
fraction of the population over time.  
HCT-116 or WiDr cells were treated as described in 2.1.2 and the medium was 
removed after the appropriate time points (usually 18, 24, 48, 72 h after light exposure). 
Growth medium containing MTT (0.25 mg/ml) was added to each well including a well 
without cells (used as a negative control). After incubation for ~3 h, the medium was removed 
and the formazan crystals were dissolved in an appropriate volume of DMSO. The samples 
were transferred to a microplate and, if necessary, diluted with DMSO to keep the absorbance 
within the linear range. The absorbance at 570 nm was measured by using a Multiscan EX 
platereader (Global Medical Instrumentation, Ramsey, MN, USA). 
 
2.5.2 Protein content measurement  
When measuring the activity (e.g. of caspase-3) or expression level of a certain protein 
(e.g. TRAIL), the measured values have to be normalised against the total protein content in 
the corresponding sample. Moreover, knowing protein concentration in each sample is 
important for protein analysis by gel electrophoresis (chapter 2.6.2.), because an equal amount 
of protein from each sample has to be applied on the gel (i.e. equal loading).   
The protein content in the sample can be determined by a colorimetric assay, where 
the intensity of the colour is proportional to the amount of protein. The protein concentration 
can thus be calculated from a standard curve based on absorbance of the known amounts of a 
standard protein like bovine serum albumin (BSA). 
The protein concentration was measured by using the DC protein assay kit II (based on 
the Lowry assay [112]) according to the manufacturer’s instructions. Briefly, 5 µl of each 
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sample lysate were added to a microplate well followed by addition of 25 µl of A’ (consisting 
of copper tartrate solution and surfactant solution) and 200 µl of B (Folin phenol reagent). 
Following  ~15 min incubation at room temperature with gentle agitation, blue colour was 
formed and the absorbance at 750 nm was measured by using the Multiscan EX platereader. 
In parallel, absorbance of standard BSA (concentration range 0-2.0 µg/µl, prepared in the 
lysis buffer) was measured.  
 
2.5.3 DNA-measurement 
The SDS-lysis buffer (described in the appendix) that was used for preparation of the 
samples for protein analysis by SDS-PAGE/Western blotting (described in chapter 2.7) is not 
compatible with the DC protein colorimetric assay (chapter 2.5.2).  Therefore, another method 
had to be used in order to assure equal loading of cells from each sample on a gel.  Thus, 
DNA (i.e. O.D. at 260 nm) instead of protein was measured in each cell lysate.  
The lysates were prepared as described in chapter 2.7.1, and a blank sample was made 
by a 2x dilution of the complete lysis buffer (see appendix for details) in distilled water 
(dH2O). All samples and the blank were diluted 25x, and O.D. at 260 nm was measured by 
using the Ultrospec 2100 pro UV/Visible spectrophotometer, which was also used to translate 
O.D. into DNA concentration (ng/µl). Each sample was measured three times, and the 
average was used as the DNA concentration.  
2.6 Statistical analysis and calculation of synergy 
When two (or more) treatments are combined, the final therapeutic effect can be: 
 
i) Greater than the sum of effects of individual treatments. This is called synergy and is 
advantageous for combined cancer therapy. 
ii) Lower than the sum of effects of individual treatments, indicating that the effects 
induced by one treatment interfere with the effects of the other treatment. This is 
antagonism.  
iii) Equal to the sum of effects of individual treatments indicating that they do not 
influence each other and therefore lead to a so-called additive effect.  
 
PCI is a combination of two treatments, photochemical treatment (PDT) and, in the present 
study, transfection of PEI/pORF-hTRAIL polyplexes. The interaction of PDT and pORF-
hTRAIL transfection in PCI was evaluated following Steel and Peckham [113]:  
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-ln of survival after each treatment was calculated, i.e. y(L) = -lnS(L), where S is the relative 
survival after a light dose L. Cell survival S, which was calculated from the experimental data 
for each light dose (L) based on the MTT-assay (chapter 2.5.1). 
For each light dose including and for non-illuminated cells (0s), -lnS of the following 
treatments was calculated: 
 
yPDT - Photochemical treatment (PDT) alone 
yTRAIL - Transfection of PEI/pORF-hTRAIL polyplexes alone 
yPCI - Transfection of PEI/pORF-hTRAIL polyplexes combined with PDT (PCI) 
 
Then the difference between the –lnS values was calculated. The purely additive effect of the 
combined treatments is supposed to be: 
 
Yadditive (L) = yTRAIL (L) + yPDT (L) = -(lnSTRAIL(L)+lnSPDT(L)) 
 
The extra effect obtained by combining these two treatments is ∆y(L) = yPCI – yadditive. When 
∆y is zero, there is no extra effect obtained by combining these treatments (i.e. no synergy, no 
antagonism). Positive ∆y indicates synergy (the effect after PCI is stronger than the simple 
sum of the effect of the two treatments). Negative ∆y indicates antagonism.  
2.7 Protein analysis by SDS-polyacrylamide gel electrophoresis and 
Western blotting 
2.7.1  Preparation of cell lysates with the SDS-lysis buffer  
HCT-116 cells were treated as described in chapter 2.1.2. The cell samples were 
prepared 2, 4, 8, 18, 24 or 45 h after light exposure by the following procedure (performed 
keeping the dishes and the samples on ice): 
1. The medium, containing the floating cells, was collected, and the floating cells were 
pelleted by centrifugation. The cell pellet was washed once with ice-cold PBS, and  
~10 µl of complete SDS-lysis buffer* was added to the pellet.  
2. The adherent cells were washed once with ice-cold PBS, and 150 µl of complete SDS-
lysis buffer was added to the cells.  Then the cells were scraped by means of a rubber 
policeman.  
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3. The cells from step 1 and step 2 were collected in one tube, and after addition of 0.7 µl 
of Benzonase (to digest DNA, which makes the lysates viscous), the tubes were 
vortexed for 3 s and incubated for 5- 10 min on ice to perform lysis. 
 
The samples were divided into ~50 µl aliquots and stored at –80oC until use, avoiding 
multiple freeze-thaw cycles.  One additional aliquot of 20 µl was designated to the DNA-
measurements (chapter 2.5.3). 
 
*Buffers are described in the appendix 
 
2.7.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
To separate proteins according to their size (molecular weight) SDS-PAGE gel 
electrophoresis was used. SDS (sodium dodecyl sulphate) unfolds the proteins and gives them 
a negative charge, allowing them to pass through the gel towards the anode during 
electrophoresis. Large proteins travel more slowly than small proteins through the pores of the 
polyacrylamide gel when current is applied. Two different gels are cast on top of each other: a 
stacking (top) gel with a low amount of polyacrylamide for stacking the proteins before 
separation (to obtain clear bands); and a separating (bottom) gel with a higher amount of 
polyacrylamide for separation of the proteins. Depending on the size of the protein to be 
analysed, the amount of polyacrylamide in the separating gel may be varied (table M3). Along 
with the samples, a molecular weight standard is always applied on the gel, which is used to 
determine the size of the separated proteins from the sample.  
SDS-PAGE gels were cast using the Mini protean 3 electrophoresis system from Bio-
Rad Laboratories (see table M4 for the recipe). To make two gels, 15 ml of the separating gel 
and 10 ml of the stacking gel was used.  
 
Table M3  Amount of acrylamide for analysis of different proteins 
Protein Size (kDa) % Acrylamide in 
separating gel 
DR5 50 - 60 12 
PARP 113 + 89 10 
Caspase-3 35 + 19/17 15 
Caspase-8 57 + 43 + 18 12 
Caspase-9 47 + 37/35 12 
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Table M4  Recipes for acrylamide gels 
% Acrylamide  % Acrylamide 
Separating gel 
10 12 15 
Stacking gel 
4 
dH2O (ml) 7.28 6.5 5.4 dH2O (ml) 6.4 
1.5 M Tris-HCl pH 8.8 (ml) 3.75 3.75 3.75 1.5 M Tris-HCl pH 6.8 (ml) 2.5 
10 % SDS stock (ml) 0.15 0.15 0.15 10 % SDS (ml) 0.1 
40 % Acrylamide/Bis (ml) 3.75 4.5 5.63 40 % Acrylamide/Bis (ml) 1 
10 % APS (µl) 75 75 75 10 % APS (µl) 50 
TEMED (µl) 7.5 7.5 7.5 TEMED (µl) 10 
Total volume (ml) 15 15 15 Total volume (ml) 10 
 
An aliquot of each sample to be analysed was thawed and heated at 95oC for 5 min. 
The sample volume that had to be applied in the different wells of a gel (taking care that equal 
protein amount from each sample was applied) was calculated based on the DNA-
measurements previously performed (see chapter 2.5.3). The most concentrated sample was 
applied using the maximal volume (45 µl), while the remaining samples were applied in a 
smaller volume according to the DNA measurements.   A sample with both the coloured 
protein marker KaleidoscopeTM (6 µl) and a biotinylated protein marker (3 µl) in 21 µl of the 
2x sample buffer* was included for each gel.  
The electrophoresis was performed in a running buffer* at 200 V with a current of 
100-200 mW for 45 min. The mini protean cell (Biorad) was placed in a tray filled with ice to 
prevent heating, which could destroy the gels and the proteins. 
 
*Buffers are described in the appendix 
 
2.7.3  Western blotting and immunodetection 
After being separated by the SDS-PAGE, the proteins were transferred from the gel to 
a Hybond-P membrane (PVDF-membrane, Amersham Biosciences) and detected by using 
specific antibodies. In the wet-blot procedure the gel-membrane “sandwich” is soaked in a 
transfer buffer*, and current moves the proteins from the gel to the membrane. 
  Before transfer, the Hypond-P membranes  (~7.0 x 9.0 cm size) were soaked in 
methanol and equilibrated in the transfer buffer together with the gels. Sponges and filters 
were also soaked in the buffer, and the transfer chambers were then assembled in the 
following order: 
  
Black plate – sponge – filter – gel – membrane– filter – sponge – transparent plate 
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The protein transfer was performed at 100 V for 70 min on ice, with continuous stirring. 
Successful transfer was confirmed visually by verifying that the KaleidoscopeTM protein 
marker was transferred from the gel to the membranes. 
 
Table M5  Conditions for immunostaining after Western blotting 
Primary 
antibody  
Dilution and buffers for the  
primary antibodies 
Dilution and type of the  
secondary antibodies 
Anti-DR5 1:200  Blocking buffer 1:2000 Anti-goat 
Anti-Caspase-8 1:1000  Wash buffer with 5 % BSA 1:5000 Anti-mouse 
Anti-Caspase-9 1:1000  Blocking buffer 1:5000 Anti-mouse 
Anti-Caspase-3 1:1000  Blocking buffer 1:5000 Anti-mouse 
Anti-PARP 1:2000  Wash buffer with 5 % BSA 1:5000 Anti-rabbit 
 
The membranes were transferred into 50-ml vials with the side that had faced the gel 
during transfer, facing inwards towards the buffer (“protein side up”), and a blocking buffer* 
was added to avoid unspecific binding. Blocking was performed by rotation of the vials for 1 
h at room temperature. The blocking buffer was replaced by a solution containing a primary 
antibody diluted in either blocking buffer or wash buffer* with 5 % BSA (see table M5), and 
the membranes were rotated at 4oC. They were then washed 3x5 min in wash buffer and 
incubated with a secondary antibody conjugated to HRP for 1 h at room temperature. The 
details for the antibody-incubations are found in table M5.  The membranes were 
subsequently washed and incubated with the Amersham ECL plusTM Western Blotting 
detection reagent. This reagent creates a chemifluorescence signal upon reaction with HRP. 
Finally the proteins were visualised by detection of the chemifluorescence using the 
Molecular Dynamics Storm 860 Scanner and the ImageQuant software from GE Healthcare. 
 
*Buffers are described in the Appendix 
 
2.7.4 Verification of equal loading after Western blotting 
After transfer, Ponceau staining was performed to confirm that an equal amount of 
cells was applied in each well. The Hybond-P membranes were soaked in Ponceau S-solution 
(0.1 % in 5 % acetic acid) for ~ 5 min before destaining in water. The membranes were 
subsequently scanned using a ScanJet 6200C from Hewlett Packard Co. (Palo Alto, CA, 
USA).  
An abundant protein (α-tubulin) was also used as a loading control and was detected 
by the help of antibodies as described in chapter 2.7.3.  
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Results 
1 Verification of the plasmids carrying the TRAIL gene  
Two different plasmids - pORF-hTRAIL and pEGFP-TRAIL - have been used in the 
present study to deliver the TRAIL gene. pORF-hTRAIL carries the TRAIL gene controlled 
by the  human Elongation factor-1α (EF-1α) promoter, while pEGFP-TRAIL carries the 
EGFP-TRAIL fusion gene controlled by the CMV promoter. For verification, the produced 
plasmids were digested with different combinations of restriction enzymes. Subsequently the 
obtained plasmid fragments were separated on an agarose gel to identify the size of the DNA 
fragments. The used enzymes and the size of the expected DNA fragments are presented in 
tables R1 and R2, and the separation of the resulting DNA-fragments is shown in figures R1 
and R2.  
Figure R1 shows the DNA bands that correspond to the expected fragments from 
pORF-hTRAIL (according to table R1), indicating successful production and purification of 
the correct plasmid.  
 
Table R1 Combination of restriction enzymes for digestion of pORF-hTRAIL. The listed 
expected size of DNA is based on the restriction map of pORF-hTRAIL (fig. M3). 
Sample Restriction Enzyme Expected size of DNA after digestion (bp) 
1 None, λ-Hind III standard (1 µg) 23 130 – 9 416 – 6 557 – 4361 – 2 322 – 2 027  
2 NotI 4058  
3 NheI 4058  
4 NotI + NheI 1700 + 2358  
5 NotI + NcoI 854 + 3206  
6 None 4058 (circular: relaxed + supercoiled)  
7 None, λ-Hind III standard (2 µg) 23 130 – 9 416 – 6 557 – 4361 – 2 322 – 2 027  
 
 
1     2     3    4    5     6     7 
Figure R1
Fragments of digested pORF-hTRAIL (as described in
table 1) separated by gel electrophoresis. Lane numbers 
correspond to sample numbers in table 1. For each sample 
~1 µg of plasmid DNA was digested for 1 h at 37oC and
separated on the 0.8% agarose gel. 
relaxed
supercoiled
4058
854
2358
+1700
3206
The digestion of pEGFP-TRAIL (shown in fig. R2) in most of the cases gave the 
correct DNA fragments, according to table R2. Only in the cases when NheI was used (lanes 
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2 and 4) some extra bands were observed (indicated by “?” in fig. R2), which might be the 
result of incomplete cleavage by NheI. Despite that, it can be assumed that the produced 
plasmid corresponds to pEGFP-TRAIL.   
 
Table R2  Combination of restriction enzymes for digestion of pEGFP-TRAIL. The listed 
expected size of DNA is based on the restriction map of pORF-hTRAIL (fig. M3). 
Sample Restriction Enzyme Expected size of DNA after digestion (bp) 
1 NotI 5607  
2 NheI 5607  
3 EcoRI 5607  
4 NotI + NheI 1655 + 3952  
5 NotI + EcoRI 891 + 4716  
6 None 5607  (circular: relaxed + supercoiled)  
7 None, λ-Hind III standard (2 µg) 23 130 – 9 416 – 6 557 – 4361 – 2 322 – 2 027  
Figure R2
Fragments of digested pEGFP-TRAIL (as described in
table 2) separated by agarose gel electrophoresis. Lane 
numbers correspond to sample numbers in table 2 and for
each sample ~0.8 µg of DNA was digested for 1 h and
applied on the 0.8 % agarose gel. 
1    2    3    4    5    6          7
relaxed
supercoiled
5607
1655
3952
891
4716
?
?
2 Analysis of the expression and effect of the photochemically 
internalised genes  
2.1 Expression of the EGFP reporter gene  
Expression of a reporter gene gives an indication about the efficiency of a transfection 
method. Therefore, the expression level of a reporter gene, like EGFP, can be used to predict 
the expression of a therapeutic gene like TRAIL transfected by the same method and under 
the same conditions. Thus, to choose the transfection conditions that could be used for the 
therapeutic TRAIL gene and to confirm that PCI works under these conditions, a reporter 
plasmid (pEGFP-N1, carrying the reporter EGFP gene) was employed first. Herein PCI 
means transfection with a PEI/plasmid DNA polyplex followed by the photochemical 
treatment (PDT) used to initiate endosomal release of the polyplexes (described in Materials 
and methods, chapter 2.1.2). 
It was first demonstrated that PCI enhances the expression of the reporter EGFP gene 
delivered as a polyplex with the nonviral vector PEI into HCT-116 cells. A dose of 
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photochemical treatment (PDT) killing 30-50% of the cells was selected to initiate PCI, since 
previous studies [17] have indicated that these photochemical doses are optimal for PCI of 
plasmids.  
No PCI PCIA
B
EGFP
positives
Green fluorescence intensity
Figure R3 The effect of PCI on expression of the reporter EGFP gene delivered by PEI into
HCT-116 cells. Fluorescence microscopy (A) and flow cytometry (B) analysis
of EGFP-expressing cells performed 2 days after treatment. The cells were
transfected with pEGFP-N1 (5 µg/ml) and either kept in the dark (No PCI) or
exposed to light (PCI).  
 
Figure R3 illustrates the transfection efficiency with the pEGFP-N1 alone and in 
combination with PCI, showing an obvious effect of PCI on EGFP expression in HCT-116 
cells. Fluorescence microscopy of HCT-116 cells receiving the pEGFP-N1 revealed that the 
cells expressed EGFP when exposed to PCI treatment, but not without PCI (fig. R3A).  
For quantification of the number of cells expressing the EGFP transgene, cells were 
analysed by flow cytometry. Dot-plots (fig. R3B) show the populations of EGFP-negative 
(left part of the plot) and EGFP-positive cells (right part of the plot) without or with PCI, 
indicating that PCI can enhance polyplex-based transfection by several folds. 
To test several PCI light doses and to find the time point when the EGFP level is the 
highest, HCT-116 cells were transfected with the PEI/pEGFP-N1 polyplexes followed by 
exposure to light for 0s, 80s and 110s (PCI). The cells were analysed for EGFP expression 1, 
2 and 3 days after the treatment (fig. R4, upper panel). In parallel, cell survival was evaluated 
(fig. R4, lower panel) to correlate the PCI effect on EGFP expression with the photochemical 
effect on cell killing. Figure R4 (upper panel) presents the quantitative results of the flow 
cytometry data.  
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Normally, the cells have no endogenous EGFP, therefore there were no cells with 
green fluorescence after PDT alone, as can be seen by the lack of the black bars (fig. R4, 
upper panel). EGFP expression in cells transfected with the pEGFP-N1 (grey bars, fig. R4 
upper panel), but not exposed to light (0s), did not change significantly with time, resulting in 
~ 4% EGFP-positive cells. On the contrary, EGFP expression in cells transfected with 
pEGFP-N1 and exposed to light (i.e. PCI) was significantly increased (resulting in 10-25% 
EGFP-positive cells) depending on the light dose and on when the analysis was performed 
(fig. R4, upper panel).  
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Figure R4 The effect of PCI on expression of EGFP (upper panel: A, C, E) and on cell survival
(lower panel: B, D, F) in HCT-116 cells. “PDT” indicates cells exposed only to
photochemical treatment as indicated in the figure. “pEGFP-N1” means the cells were
treated with the PEI/pEGFP-N1 polyplexes (2.5 µg/ml pEGFP-N1) followed by the
photochemical treatment. On day 1 (A, B), 2 (C, D) and 3 (E, F) after treatment, the cells
were analysed for EGFP expression by flow cytometry or for cell survival by the MTT
assay. MTT-results are shown relative to untreated cells. The error bars represent the
standard error (SE) of three parallels in the same experiment.  
These data indicated that EGFP expression reaches the maximum approximately 2 
days after PCI, although the PCI-dependent enhancement could be seen already 1 day after 
PCI. Moreover, the effect of the higher light dose (110s) on EGFP expression seems to be 
“delayed” in respect to the lower light dose (80s). This might indicate that longer 
illumination, which leads to higher cytotoxicity (Fig. R4D,F), has a stronger temporal-
inhibitory effect on EGFP translation than shorter illumination.   
The toxicity induced by PDT, as measured by the MTT assay, was also most 
pronounced 2 days after the treatment (fig. R4, lower panel, black bars). Moreover, 
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PEI/pEGFP-N1 polyplexes did not induce any additional cytotoxicity (no difference between 
the black and grey bars in fig. R4, lower panel), indicating that the polyplexes are not toxic 
when they carry a reporter gene, and that the toxicity observed is determined only by the 
photochemical treatment.  
These results indicated that the tested transfection conditions were suitable for PCI, 
and could be used for PCI with the therapeutic, pro-apoptotic gene TRAIL. 
 
2.2 Expression and effect of the therapeutic TRAIL gene  
The effect of PCI on the expression of the therapeutic TRAIL gene delivered with the 
PEI/pORF-hTRAIL polyplexes was measured with an ELISA-assay as described in Materials 
and methods (chapter 2.3.3). The level of TRAIL protein following transfection alone or in 
combination with PCI was evaluated both in the growth medium (excreted soluble TRAIL) 
and in the lysate of HCT-116 cells (cellular TRAIL) as shown in figure R5.  
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Figure R5 The effect of PCI on the level of TRAIL expression in HCT-116 cells.  The cells
were treated with the photosensitiser followed by the incubation with the
PEI/pORF-hTRAIL polyplexes (2.5 µg/ml pORF-hTRAIL) and exposure to light
as indicated in the figure. The amount of TRAIL in the cell lysates and in the
medium was measured 1 day after the treatment. Protein content in the lysates
(relative to untreated cells) was used as an indication of cell survival (dots, right y-
axis). The graph represents one experiment with one sample per treatment. 
 
Untreated cells had little endogenous TRAIL protein (~ 0.5 pg TRAIL in both the 
medium and the cell lysate per µg protein in the lysate) (fig. R5). Upon transfection with 
pORF-hTRAIL without PCI (0s illumination), ~ 1 pg TRAIL per µg protein in the cell lysate 
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was found in both medium and lysate, while with PCI, the expression of TRAIL in the cell 
lysate increased by 2.5 and 3.5-fold after light doses of 80s and 110s, respectively. However, 
the level of TRAIL protein secreted into the growth medium remained stable, ~ 1 pg TRAIL 
per µg protein regardless of the light dose. Photochemical treatment alone (PDT) did not 
influence the TRAIL expression (data not shown).  
These results indicated that PCI enhances the level of TRAIL protein in HCT-116 
cells transfected with pORF-hTRAIL. The enhancement corresponded to the fold 
enhancement observed with the EGFP reporter gene (fig. R4A). Moreover, most of the 
TRAIL protein was shown to stay in the cells and was not excreted into the medium.  
To be certain that the expressed pro-apoptotic TRAIL protein was functional and 
could induce cell death, the cytotoxic effect of PCI of pORF-hTRAIL was evaluated and 
compared to the cytotoxic effect of the photochemical treatment (PDT) alone. Two different 
concentrations (2.5 µg/ml and 5 µg/ml) of pORF-hTRAIL were employed, and the decrease 
in cell survival was analysed 1, 2 and 3 days after treatment. As can be seen in figure R6, 
transfection with pORF-hTRAIL killed HCT-116 cells both alone and in combination with 
PCI, with an overall enhancement of cell death when PCI was applied. One day after 
treatment (fig. R6A) the survival curves for PDT and PCI with 2.5 µg/ml of pORF-hTRAIL 
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Figure R6 The effect of PCI of pORF-hTRAIL on the survival of HCT-116 cells. “pORF-
hTRAIL” means treatment with PEI/pORF-hTRAIL polyplexes (2.5 µg/ml and 5 
µg/ml) followed by the photochemical treatment as indicated. “PDT” means only
photochemical treatment. Survival was measured 1, 2 and 3 days (A, B and C) after
treatment. The error bars represent the SE of 1-4 experiments with one sample per 
treatment. Lack of error bars indicates one experiment.  
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were overlapping, indicating that only photochemical treatment and not TRAIL at this dose 
caused the cytotoxicity. However, when the pORF-hTRAIL dose was doubled, an obvious 
effect of the TRAIL protein was observed leading to ~40 % cytotoxicity without PCI and up 
to ~70 % cell death with PCI using the highest light dose (110s). For comparison, PDT 
induced ~45 % death at the same light dose. Two days after treatment (fig. R6B) both 
2.5 µg/ml and 5 µg/ml of pORF-hTRAIL had a pronounced effect on cytotoxicity, leading to 
~20 % and ~40 % cell death, respectively, without PCI and increasing to >70 % and >90 % 
cell death, respectively, with PCI. For comparison, PDT-induced cytotoxicity was lower 
(black dots in figure R6B). Three days after treatment, only 5 µg/ml of pORF-hTRAIL gave a 
significantly higher cytotoxicity compared to PDT-induced cytotoxicity.  
 
Table R3 Statistical evaluation of the toxicity induced by PCI transfection of the TRAIL gene 
versus the toxicity induced by single treatments: PDT alone or transfection with 
pORF-hTRAIL alone. Negative ∆y indicates an antagonistic effect of PCI, ∆y of zero 
indicates a purely additive effect and positive ∆y indicates synergy. P-values were 
obtained using the paired t-test. The points marked with * are statistically significant 
(p<0.05) while the ¤ implies that there was only one sample and therefore it was not 
possible to calculate SE or p-values.  
A   2.5 µg pORF-hTRAIL / ml ∆y SE p-value 
0 s -0.03 0.03   
80 s* -0.09 0.04 0.034 Day 1 
110 s -0.17 0.10 0.488 
0 s 0.04 0.03   
80 s* 0.45 0.07 0.002 Day 2 
110 s* 0.45 0.15 0.020 
0 s -0.03 ¤   
80 s 0.33 ¤ ¤ Day 3 
110 s 0.97 ¤ ¤ 
B    5 µg pORF-hTRAIL / ml ∆y SE p-value 
0 s 0.07 0.04   
80 s* -0.12 0.19 0.415 Day 1 
110 s 0.02 0.04 0.673 
0 s 0.02 0.03   
80 s* 0.27 0.18 0.196 Day 2 
110 s* 0.45 0.25 0.162 
0 s -0.01 ¤   
80 s 0.22 ¤ ¤ Day 3 
110 s 1.01 ¤ ¤ 
 
These data indicated that the photochemically internalised TRAIL gene was 
functional, and could lead to cell death in a light-dose dependent manner. In addition, the 
resulting cytotoxicity was much higher when 5 µg/ml of pORF-hTRAIL was employed 
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compared to 2.5 µg/ml of pORF-hTRAIL, which gave a quite good effect, but only 2 days 
after treatment.   
The survival data presented in figure R6 were also used to calculate whether pORF-
hTRAIL and photochemical treatment act synergistically in PCI, or whether a purely additive 
effect of the combined pEGFP-hTRAIL and PDT on cell death is achieved (table R3). 
Interestingly, statistically significant synergy (positive ∆y) was only detected with the lowest 
dose (2.5 µg/ml) of pORF-hTRAIL, and only 2 days after PCI (see table R3). There was also 
an indication of synergy 3 days after PCI for both concentrations, but since only one 
experiment was performed the result was not statistically significant.  
Summarising, the data indicated that 5 µg/ml of pORF-hTRAIL combined with PCI 
gives a stronger overall effect on cell death, whereas 2.5 µg/ml of pORF-hTRAIL gives a 
lower, but synergistic effect on cell death. Synergy might be very important in therapeutic 
situations when the highest specificity of the treatment is needed. Thus, in the present study 
both 2.5 µg/ml and 5 µg/ml of pORF-hTRAIL were used depending on the specific goal of 
the experiment.  
 
 
2.3 Expression of the EGFP-TRAIL reporter-therapeutic fusion gene 
 The effect of PCI on the expression of the fusion gene, containing both the reporter 
EGFP gene and the therapeutic TRAIL gene, was studied employing PEI/pEGFP-TRAIL 
polyplexes. The fusion gene would allow for tracking of EGFP-expressing cells, that should 
also express the TRAIL protein, and to analyse apoptosis in the EGFP-positive and the EGFP-
negative cells. The PCI effect on EGFP expression was tested by flow cytometry (fig. R7A), 
while the PCI effect on TRAIL protein expression was tested by the MTT assay, measuring 
the killing potential of TRAIL (fig. R7B).  
The results (obtained 2 days after treatment) showed that the expression of EGFP from 
pEGFP-TRAIL was negligible compared to EGFP-expression from the pEGFP-N1 under the 
same conditions (fig. R7A). The intensity of the EGFP fluorescence detected after PCI of the 
pEGFP-TRAIL was also lower than the intensity after transfection with pEGFP-N1, and 
similar results were obtained 1 or 3 days after treatment (data not shown). This might suggest 
that the processing of the fusion gene EGFP-TRAIL does not result in properly folded EGFP, 
which could fluoresce green.  
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The TRAIL-moiety of the fusion gene seemed to be expressed to a larger extent than 
the EGFP moiety. However, transfection with pEGFP-TRAIL without PCI induced ~ 20 % 
cell death, which was approximately 2-fold less than the > 40 % toxicity induced by pORF-
hTRAIL (fig. R7B). PCI of the pEGFP-TRAIL did not lead to higher cytotoxicity either, 
compared to PCI of pORF-hTRAIL. This indicated that the pORF-hTRAIL plasmid is more 
potent than pEGFP-TRAIL in inducing cell death both alone and in combination with PCI. 
Therefore, pORF-hTRAIL was chosen for the following studies of apoptosis and molecular 
mechanisms. 
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Figure R7 The effect of PCI on EGFP expression (A) measured by flow cytometry, and on cell
survival (B) measured by the MTT assay after transfection with pEGFP-TRAIL. For
comparison, EGFP expression following transfection with pEGFP-N1 (A) and
survival following transfection with pORF-hTRAIL (B) is presented. Analysis was
performed 2 days after treatment. All plasmids were at a concentration of 5 µg/ml.
Survival was relative to untreated cells. One representative experiment out of three
is presented.  
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3 Analysis of apoptosis 
The previous section showed that the cells produced an enhanced level of the TRAIL 
protein following PCI of pORF-hTRAIL (fig. R5) resulting in enhanced cell death (fig. R6). 
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Figure R8 Fluorescence microscopy micrographs showing apoptotic nuclei in HCT-116 cells treated
as indicated in the figure and stained with Hoechst 33342 immediately before analysis (A-
C, C shows cells floating in the medium) 1 and 2 days after treatment as indicated. Close up
of two apoptotic nuclei (D) (from the upper right corner of “PDT” in B). Corresponding cell
survival was measured by means of the MTT assay (E) 2 days after treatment and releated
to untreated cells. “pORF-hTRAIL” indicate cells transfected with the PEI/pORF-hTRAIL
polyplexes without PCI. “PDT” indicates cells treated photochemically without plasmid.
5 µg/ml of pORF-hTRAIL was used where indicated. Arrows point to cells with apoptotic
nuclei.  
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To investigate the intensity of apoptosis after PCI-transfection of pORF-hTRAIL compared to 
transfection without PCI and to PDT alone, apoptosis was assayed by three different methods: 
fluorescence microscopy of cells stained with Hoechst 33342, quantification of caspase-3 
enzymatic activity and analysis of the fraction of cells in SubG1.  
 
3.1 Fluorescence microscopy of Hoechst 33342-stained cells 
To visualise the apoptotic cells (i.e. apoptotic nuclei) the cells were transfected with 
the pro-apoptotic pORF-hTRAIL alone or in combination with PCI, or the cells were exposed 
to photochemical treatment alone (PDT) followed by staining with the Hoechst 33342 as 
described in Materials and methods (chapter 2.4.1). Figure R8 shows cells analysed 1 
(fig. R8A) and 2 (fig. R8B,C) days after treatment. The arrows point to the cells containing 
condensed clumped DNA, indicating apoptotic nuclei like the ones shown in figure R8D.  
As can be seen, untreated cells had no apoptotic nuclei. However, when the cells were 
transfected with pORF-hTRAIL without PCI, some cells with apoptotic nuclei could be 
observed already after 1 day, and the amount of cells in apoptosis increased after 2 days. This 
implies that some time is needed before the internalised pORF-TRAIL is expressed into the 
TRAIL protein and before the TRAIL protein induces apoptosis. When transfection with 
pORF-TRAIL was combined with PCI, most of the cells had condensed nuclei already after 1 
day. PDT also seemed to be efficient at inducing apoptosis, as judged by apoptotic nuclei 1 
day after PDT, but to a slightly lower extent than the PCI-treatment.  
It should be noted that the cell survival (fig. R8E) was low in this particular 
experiment: PDT killed ~ 70 % of the cells and PCI killed almost 90 %. This can also be seen 
in the micrographs, where the amount of cells is dramatically decreased in the PDT/PCI-
samples compared to the untreated cells. Low cell survival might also indicate that the 
difference between PCI- and PDT-induced apoptosis might be higher under photochemical 
conditions optimal for PCI (i.e. killing ~ 50 % of the cells [17]) 
These data illustrated that all three treatments – PCI-transfection of pORF-hTRAIL, 
transfection of pORF-hTRAIL alone, and photochemical treatment (PDT) – lead to the 
morphological changes characteristic of apoptosis, and that these changes can already be 
detected 1 day after treatment becoming more evident 2 days after treatment, which 
corresponds to the earlier presented data (figs. R4 and R6). 
 
3.2 Activation of Caspase-3  
Caspase-3 is the main executioner caspase (Introduction, chapter 2.1), and its activity 
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can hence be used as a measure of induced apoptosis. To evaluate the activation of caspase-3 
following transfection with pORF-hTRAIL polyplexes (alone or in combination with PCI) 
and PDT alone, an enzymatically based caspase-3 assay was used as described in Materials 
and methods (chapter 2.4.3). This assay consists of a substrate for active caspase-3, which is 
linked to a fluorescing protein, and, upon cleavage of the substrate, fluorescence appears and 
can be measured. The fluorescence is proportional to the caspase-3 activity.  
As can be seen in figure R9, in HCT-116 cells the activation of caspase-3 1 day after 
treatment was very low (not exceeding 1.5-fold) regardless of treatment, even though the 
effect on cell survival was obvious: PDT employing 110s of light killed ~ 50 %, and PCI of 
pORF-hTRAIL employing the same light dose killed  ~ 60 % of the cells.  Analysis 
performed 4 hours and 2 days after treatment also showed similar results to the ones presented 
in figure R9 (data not shown).  
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Figure R9 The effect of transfection with 2.5 µg/ml pORF-hTRAIL (alone or in
combination with PCI) and treatment with PDT alone on caspase-3 activation
(A) and on cell survival (B) in HCT-116 cells. The activity of caspase-3 and
cell survival was measured 1 day after treatment and is relative to untreated
cells. Error bars represent the SE of 1-3 different experiments with one sample
per treatment. Lack of error bars indicates one experiment.  
 
To investigate whether the low activation of caspase-3 was a phenomenon of the 
HCT-116 cells, or an artefact related to the detection method, similar experiments were 
performed on another cell line – the colon carcinoma WiDr cells. These cells are generally 
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less sensitive to transfection with PEI/plasmid polyplexes than HCT-116 (data not shown), 
therefore, 5 µg/ml of pORF-hTRAIL was used for transfection of the WiDr cells.  
Figure R10 shows that in the WiDr cells, the activity of caspase-3 increased with 
increasing light dose. PCI using 110s illumination (killing ~ 70 % of the cells) induced a 10-
fold increase in the activity of caspase-3, whereas the corresponding PDT-dose (killing ~ 
60 % of the cells) induced only a 3-fold increase. This indicated that the caspase-3 enzymatic 
assay detects the activation of caspase-3. Therefore, one may assume that in HCT-116 cells 
caspase-3 is not notably activated, neither by PCI of pORF-hTRAIL nor by PDT alone or 
pORF-hTRAIL alone. These results also indicated that there is a difference between these two 
cell lines regarding the apoptotic pathway, and in the way different apoptosis-related 
components respond to PCI/PDT.  
A
R
el
at
iv
e 
ca
sp
as
e-
3-
ac
tiv
ity
 
0
2
4
6
8
10
12
No plasm id (PDT)
pORF-hTRAIL
B
Light dose (s)
0 80 110
%
 S
ur
vi
va
l
0
20
40
60
80
100
120
PCI - +                +
R
el
at
iv
e 
ca
sp
as
e-
3-
ac
tiv
ity
 
%
 S
ur
vi
va
l
Figure R10 The effect of transfection with 5µg/ml pORF-hTRAIL (alone or
in combination with PCI) or PDT alone on caspase-3 activation
(A) and on cell survival (B) in WiDr cells. The activity of
caspase-3 and cell survival was measured 1 day after treatment
and related to untreated cells. Error bars represent the SE of two
different experiments.  
                                                                                     
3.3  SubG1-analysis    
To quantify the fraction of cells undergoing apoptosis, the cells containing less DNA 
(i.e. SubG1 cells) were identified by flow cytometry as described in Materials and methods 
(chaper 2.4.2). Figure R11A shows histograms illustrating how the SubG1 cell fraction was 
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Figure R11 Histograms from flow cytometry analysis of SubG1 cell fraction (A) in HCT-116
cells 2 days after treatment (data from one representative experiment) and
corresponding cell survival (B). The numbers in A indicate the percentage of cells
in    SubG1. “pORF-hTRAIL” indicate cells transfected with PEI/pORF-hTRAIL
polyplexes without photosensitiser. 5 µg/ml of pORF-hTRAIL was used. 
 
calculated. In each histogram, the amount of cells (y-axis) is plotted against the intensity of 
PI-fluorescence indicating the cellular DNA content (x-axis). The fraction of cells in SubG1 
(indicated by the vertical bar “M1”) has less DNA than cells in G1. As can be seen, the 
percentage of cells in SubG1 (found by using the CellQuest software) depended on the 
treatment. PCI seemed to be the most efficient, resulting in the largest SubG1 cell fraction 
(fig. R11A). This correlated to the survival data presented in figure R11B, showing the 
strongest killing efficiency of PCI transfection of pORF-hTRAIL compared to PDT alone or 
pORF-hTRAIL alone.  
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In figure R12, the combined result of SubG1-analysis from four different experiments 
(upper panel), and the corresponding cell survival (lower panel) is presented. The SubG1 data 
reflects apoptotic death, and the cell survival data reflects the overall toxicity, i.e. death via 
both apoptosis and necrosis. The SubG1 fraction and the survival were measured 1, 2 and 3 
days after various treatments.  
The results showed that the fraction of apoptotic cells generally increased with 
increasing concentration of pORF-hTRAIL and with increasing light dose (fig. R12, upper 
panel). The toxicity curves depicted a similar dependency. In general, the strongest effects on 
apoptosis and cell death were detected 2 days after treatment (fig. R12C, D). As can be seen 
in figure R12 (upper panel), pORF-hTRAIL transfection alone (using 2.5 µg/ml or 5 µg/ml of 
pORF-hTRAIL) led to ~ 20 % and ~ 40 % apoptotic cells, respectively. When PCI was 
employed, the fraction of apoptotic cells increased significantly, resulting in 70-80 % 
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Figure R12 Quantification of SubG1-fraction (upper panel) and corresponding cell survival (lower
panel) in HCT-116 cells after transfection with pORF-hTRAIL (2,5 µg/ml or 5 µg/ml,
alone or in combination with PCI) (using two different light doses). The samples were
analysed 1 (A+B), 2 (C+D), and 3 (E+F) days after treatment. The survival data are
based on the same data as in figure 6 and are relative to untreated cells. The error bars
represent the SE of 1-4 experiments with one sample per treatment. Lack of error bars
indicates one experiement.  
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apoptotic cells (fig. R12C,E). However, the photochemical treatment alone (PDT) was also 
quite efficient in inducing apoptosis (fig. R12, upper panel, black bars) though slightly less so 
than PCI. The induction of apoptosis correlated to the toxicity data: PCI eliminated 70-90 % 
of the cells (fig. R12D,F), while PDT induced 40-60 % cytotoxicity (fig. R12D,F) depending 
on the light dose and on the analysis time.  
 
3.3.1 PCI of the TRAIL gene employing the “light first” strategy  
 
 As an alternative to the regular PCI-procedure, where the illumination is performed 
after treatment with the polyplexes, the illumination may be performed before administration 
of the PEI/DNA polyplex (“light first”, fig. I2) [7]. This approach was briefly tested and both 
SubG1 and cell survival were analysed to see whether “light first” would improve the 
therapeutic effect of PCI with pORF-hTRAIL. The data showed that the fraction of cells in 
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Figure R13 SubG1-fraction (A) and corresponding cell survival (B) measured
two days after treatment with “light first” PCI-procedure. The
concentration of pORF-hTRAIL was 5 µg/ml. The survival was
relative to untreated cells. One experiment was conducted with
the light doses 60 and 80s, and one with 80 and 110s. Error bars
represent the SE of two independent experiments with one sample
per treatment. 
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SubG1 increased depending on the light dose (fig. R13A). However, only a negligible 
difference between PCI and PDT could be observed (fig.R13A), even though there was a 
strong effect of PCI compared to the PDT effect on the overall cell death (fig. R13B). 
Comparison of figures R12 and R13 revealed that “light first” does not lead to higher 
cytotoxicity than “light after”, and therefore the “light first” approach was not explored 
further.  
 
 4 Effect of PCI on the level of apoptosis-related molecules – a 
study by Western blotting 
In order to investigate the apoptotic death pathway at the molecular level in HCT-116 
cells after transfection with PEI/pORF-hTRAIL polyplexes (alone or in combination with 
PCI) or photochemical treatment (PDT), the involvement of various apoptosis-related 
molecules was analysed at different time points after treatment. The idea was to find out 
whether, and how fast, the level of key apoptosis-related proteins was affected by the 
treatments.  
+          +          - - +          +           - Photosensitiser
+           + +         +           - - - pORF-hTRAIL 
+      - +         - +       - - 110s illumination 
PCI  pORF-hTRAIL       PDT         Controls
Figure R14 Representative Ponceau staining of a membrane used for Western blotting (the
same as in figures R18 and R20, 45 h). Samples were treated as indicated.
5 µg/ml of pORF-hTRAIL was used.  
The proteins selected for further analysis were: 
o DR5, main death receptor (DR) for the TRAIL-protein 
o Caspase-8, the main initiator caspase in DR-mediated apoptotic pathways 
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o Caspase-9, the main initiator caspase for mitochondria-mediated apoptosis 
o Caspase-3, the main executioner caspase 
o PARP, a key death substrate (apoptosis inducing enzyme) cleaved by executioner 
caspases  
 
The activation of caspases can be detected by the reduced level of procaspases and by 
the appearance of cleaved fragments, i.e. active caspases. Both pro- and cleaved forms of 
caspases can be detected by Western blot analysis, as it was attempted to show below. 
For evaluation of the treatment effect on the level of selected proteins, it is important 
that the same amount of total protein is applied from all the samples, regardless of treatment. 
Thus, equal loading was first confirmed by Ponceau staining, where all the separated proteins 
on a representative gel are visualised (as shown in fig. R14). Especially the strongest bands 
(indicated with arrows) appear to be equal independent of the treatment, indicating that an 
equal amount of total protein was applied in each well. Alternatively, equal loading can be 
confirmed by detection of an abundant cellular protein like α-tubulin, as it is demonstrated in 
figure R18B.  
 
4 h DR5
8 h v DR5
18 h DR5
24 h
DR5
Photosensitiser     - +        +     - - +        +
pORF-hTRAIL                  - - - +       +       +       +
110s illumination                - - +     - +    - +
Controls              pORF-hTRAIL 
PDT                               PCI
Figure R15 Expression of DR5 (MW ~50 kDa) in HCT-116 cells analysed 4, 8, 18 and
48 h after treatment. The samples were treated as indicated in the figure. A
pORF-hTRAIL concentration of 5 µg/ml was used.  
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4.1 Death receptor 5 
DR5 is involved in initiation of the extrinsic apoptotic pathway characteristic for the 
TRAIL protein. Consequently, the level of DR5 might influence TRAIL-mediated apoptosis 
and, therefore, DR5 expression was evaluated in this study. The expression of DR5 was 
clearly up-regulated by photochemical treatment (110s illumination), i.e. both PCI-and PDT-
treated cells showed an elevated level of DR5 as can be seen in figure R15 (the circles point 
out the strongest bands corresponding to DR5). The cells treated with PDT alone seemed to 
have a slightly higher up-regulation of DR5-level than the cells treated with PCI. The up-
regulation was notable already 4 h after light exposure, peaked after 8 h and persisted until 
48 h, though at a lower level.  
These data suggest that the photochemical treatment used in PCI also stimulate the 
expression of DR5 and thus might sensitise the cells to apoptosis via death receptors.  
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Figure R16 Effect of a blocking peptide on the detection of the DR5-bands
in Western blots. “PDT” means the cells were treated with the
photosensitiser followed by 110s illumination, “control”
means untreated cells. Blots are without (A) or with (B) the
DR5-specific blocking peptide added in 5x excess to a 1:5000
dilution of the primary antibody. 
  To confirm that the photochemically up-regulated bands observed in figure R15 were 
DR5 bands, a DR5 blocking peptide was used (fig. R16). The blocking peptide is recognised 
by the primary antibody and therefore blocks the binding of the primary antibody to DR5. As 
a result, DR5 bands cannot be seen on Western blots, as was demonstrated in figure R16B. 
The band that was stronger in PDT-treated cells than in untreated cells, and thus were 
expected to be the DR5 band (fig. R16A), disappeared when the blocking peptide was applied 
(fig. R16B) indicating that this band was indeed DR5.   
  
4.2 Caspase-8 
To investigate the involvement of the extrinsic pathway following various treatments, 
the level of the main initiator caspase of the extrinsic pathway, caspase-8, was analysed. As 
can be seen in figure R17, the level of procaspase-8 did not change significantly regardless of 
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treatment. However, bands corresponding to cleaved fragments, i.e. active caspase-8, were 
observed in the PCI-treated samples 18 h after treatment, and were still apparent after 45 h 
(fig. R17, cleavage product indicated with circles). After 24 h, cleavage products were 
detected after PCI (fig. R17, 24h A+B). PDT also gave rise to bands corresponding to active 
caspase-8 (fig. R17, 24h B), but these bands were only present in this one blot (missing in fig. 
R17, 24h A), and had disappeared 45 h after PDT.  
These data suggested that PCI of the PEI/pORF-hTRAIL polyplexes is more efficient 
in activating caspase-8 as compared to PDT alone or pORF-hTRAIL alone.  
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Figure R17 The level of caspase-8 in HCT-116 cells analysed 2, 4, 8, 18, 24 and 45 h
after treatment. The cells were treated as indicated in the figure, and the
level of both procaspase-8 (MW 57 kDa) and caspase-8 (MW 43/41 kDa)
was detected. 5µg/ml pORF-hTRAIL was used where indicated 
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4.3 Caspase-9   
         
To investigate the involvement of the intrinsic pathway following various treatments, 
the level of the main initiator caspase of this pathway, caspase-9, was analysed. However, the 
procaspase-9 and the cleaved (active) fragments proved to be difficult to analyse by the 
antibodies used in the present study. Figure R18 shows that the bands corresponding to pro- 
and active caspase-9 were very weak, making it difficult to observe changes after various 
treatments. Moreover, it seemed that both procaspase-9 and the large fragment of active 
caspase-9 were present in all the samples regardless of treatment.  
Procaspase-9 was more easily detected in another experiment using membranes 
different from the ones previously used (fig. R18B). There seemed to be some changes in the 
intensity of the procaspase-9 bands depending on the treatment, the fragments of active 
caspase-9 were not detected though. In general, reduced levels of procaspase-9 (indicating 
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18 h Procaspase-9
Active caspase-9
Active caspase-9
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Procaspase-9
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Active caspase-9
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PCI          pORF-hTRAIL                PDT             Controls
Figure R18 The level of procaspase-9 (MW 47 kDa) and active caspase-9 fragment (MW
35/37 kDa) in HCT-116 cells 18, 24 and 45 h after treatment. A and B present
different membranes (i.e. different Western blots). As a loading control, α-
tubulin (MW 50 kDa) was used (B, 45h). Circles indicate samples with lower
level of procaspase-9 than in samples not exposed to the photochemical
treatment. The cells were treated as indicated in the figure. 5 µg/ml pORF-
hTRAIL was used where indicated. The membranes shown in B were previously
used for PARP-detection (fig. R20). 
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caspase-9 activation) were observed after PCI and PDT as compared to samples where no 
photochemical treatment was applied (except untreated cells, which might be an artefact) 
(fig. R18B). To check if the reduction in the level of procaspase-9 was in fact the result of the 
PDT/PCI treatment and not due to less protein loaded on the gel, one of the membranes 
(fig. R18B, 45h) was used to detect α-tubulin as a loading control. As can be seen in the 
image from 45 h (fig. R18B), the intensities of the α-tubulin bands were quite similar for all 
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Figure R19 The level of caspase-3 in HCT-116 cells analysed 2, 4, 8, 18, 24 and 45
hours after treatment. The cells were treated as indicated in the figure, and
the level of procaspase-3 (35 kDa) was detected. 5µg/ml pORF-hTRAIL
was used where indicated 
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the samples. This indicated that the same amount of total protein from the PCI/PDT samples, 
and from the samples not exposed to photochemical treatment were loaded on the gel, 
confirming the result obtained with Ponceau staining (fig. R14).  
All together this indicates that caspase-9 might be activated by photochemical 
treatment, as could be expected according to the literature [45], as well as by PCI. However, 
the results are not convincing and indicate that more sensitive detection methods are generally 
needed to capture the activation of this caspase.  
 
4.4 Caspase-3  
To investigate the activation of the main executioner caspase, caspase-3, the levels of 
procaspase-3 and cleaved (active) caspase-3 were evaluated. The enzymatic caspase-3 assay 
(chapter 3.2) did not reveal significant caspase-3 activation in HCT-116 cells. Likewise, 
Western blot analysis did not show any cleaved forms of caspase-3 (fig. R19). Only the bands 
corresponding to procaspase-3 were observed in all the samples, and the level of procaspase-3 
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Figure R20 The level of PARP in HCT-116 cells 2, 4, 8, 18, 24 and 45 h after treatment.
The cells were treated as indicated in the figure, and the level of both full-
length PARP (113 kDa) and active PARP fragment (89 kDa, indicated by
circles) was detected. 5 µg/ml of pORF-hTRAIL was used.  
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did not change following various treatments. These data confirmed that caspase-3 is not 
strongly activated by the tested treatments in HCT-116 cells.  
 
4.5 PARP 
 the apoptosis-inducing enzyme Poly (ADP-ribose) polymerase (PARP) is 
one of 
                    
Cleavage of
the final stages in the apoptotic death pathway, performed by executioner caspases like 
caspase-3. Therefore, the level of PARP was evaluated at different time points after 
transfection of PEI/pORF-hTRAIL polyplexes (alone or in combination with PCI) and after 
PDT. As can be seen in figure R20, full length PARP was present in all the samples, 
indicating that none of the treatments induced complete cleavage of PARP. Despite generally 
weak bands, it appeared that only PCI induced PARP cleavage (indicated in fig. R20 with 
circles), which could be detected 18 and 24 h after treatment. These data support the earlier 
observations that PCI of PEI/pORF-hTRAIL polyplexes could induce apoptosis more 
efficiently than transfection with only pORF-hTRAIL or PDT alone.                                             
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Discussion                                                                                                   
Photochemical internalisation (PCI) is a well-tested strategy for delivery of 
macromolecules to target cells, which enables the macromolecules to escape from endocytic 
vesicles where they would otherwise be degraded. Efficacy of macromolecular therapy is 
therefore highly improved employing PCI. This strategy also provides specificity i.e. allows 
targeting of macromolecular therapies only to illuminated areas. Therefore, PCI is especially 
attractive for delivery of cytotoxic molecules as used in cancer treatment.  
The aim of the present study was to evaluate the potential of PCI for enhancement of 
the delivery, expression and, consequently, the effect of a therapeutically relevant gene, aimed 
at inducing apoptotic death in cancer cells. In that respect, PCI was used for delivery of the 
pro-apoptotic gene TRAIL in the form of polyplexes consisting of the pORF-hTRAIL 
plasmid and the nonviral vector PEI. This work was partially based on another similar study 
by Engesæter et al. (submitted), who delivered the TRAIL gene by the help of PCI, however, 
employing an adenoviral vector. The authors demonstrated that PCI of the TRAIL-adenovirus 
significantly enhanced the induction of apoptosis and led to a synergistic increase in cell 
death. On this basis, it was relevant to study whether comparable results could be achieved 
with a “safe”, i.e. non-viral vector.  
Here it was demonstrated that in the colon carcinoma cell line HCT-116, PCI enhances 
both the expression of TRAIL (at least 3.5-fold, fig. R5) and the cytotoxic effect compared to 
cytotoxicity induced by pORF-hTRAIL polyplexes without PCI (fig. R6) or photochemical 
treatment (PDT) without pORF-hTRAIL (figs. R6 and R12). It was also demonstrated by 
several different assays for detection of apoptosis that PCI was the strongest inducer of 
apoptosis as compared to the other two treatments. Although studies of apoptosis at the 
molecular level, e.g. investigating activation of various caspases, did not show an obvious 
effect of any of the treatments, only PCI (to some extent also PDT) resulted in low, but 
detectable effects. For example, indications of active caspase-8 or cleaved PARP (figs. R16 
and R19) were stronger after PCI than after PDT, whereas transfection with pORF-hTRAIL 
without PCI did not show any effect. These data do not exclude the possibility that individual 
treatments, like PDT or transfection with pORF-hTRAIL, also induce the hallmarks of 
apoptosis, but, the data indicate that the effect of the individual treatments was below the PCI-
mediated level, and below the detection limit of the employed assays.  
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The strongest effect on cell death was registered when a relatively high dose (5 µg/ml) 
of pORF-hTRAIL was combined with PCI. In this case, cell death was approaching 100% 
two-three days after PCI (fig. R6). However, the high dose of pORF-hTRAIL without PCI 
also killed ~50% of the cells. This might be not desirable in many therapeutic situations, 
where non-target cells have to be preserved. In this regard, it has been shown before [16] that 
a relatively low dose of plasmid DNA and the PEI vector (with a low PEI:DNA ratio 
compared to the ratio employed if PEI is used alone [54, 114]) might be especially attractive 
for specific killing, since only PCI-treated cells are affected.  Low concentrations of PEI 
would not be expected to have an effect on cell death, as low doses of PEI are unable to 
release the plasmid unless PCI is performed. This allows for high therapeutic specificity, in 
that only tumour cells are affected due to PCI, while the normal cells are preserved due to the 
absence of PCI. In the present study, such a low concentration was found to be 2.5 µg/ml 
pORF-hTRAIL, which induced only 10-20 % killing without PCI and 70 % killing with PCI 
(fig. R5). In addition, the low concentration induced a synergistic killing effect when 
combined with PCI. It should be noted that generally, an additive or only slightly synergistic 
effect (using 2.5 µg/ml pORF-hTRAIL) was obtained when pORF-hTRAIL was delivered by 
the help of PCI. This means that the enhanced cytotoxicity achieved by PCI-mediated 
transfection of the pORF-hTRAIL polyplexes was mostly a sum of cytotoxicities induced by 
the two individual treatments: photochemical treatment and transfection of pORF-hTRAIL. 
One would, however, expect a more pronounced synergistic effect on cell death following 
PCI of pORF-hTRAIL based on the following facts: 
i) PCI enhanced the level of the expressed TRAIL protein so that more TRAIL was 
available for initiation of apoptosis in PCI-treated cells  
ii) Photochemical treatment initiating endosomal release also stimulated the expression 
of the TRAIL death receptor DR5 (responsible for induction of apoptosis by TRAIL), 
which could sensitise the PCI/PDT-treated cells to TRAIL.  
The lack of significant synergistic effect could have several explanations as discussed 
below: 
 
1) The expressed TRAIL protein stays associated with the cells and is not excreted into the 
medium (fig. R5). This “entrapment” of the TRAIL protein could be one of the explanations 
for the lower-than-expected cytotoxic effect of PCI despite of up-regulated DR5. The cellular 
“entrapment” of TRAIL indicates that it does not induce a bystander killing effect on the 
 72
Discussion 
neighbouring cells that do not receive or express the TRAIL gene. The “entrapped” TRAIL 
could also explain why the best cytotoxic effect was registered two days after treatment, while 
the effect tended to weaken at the later time points (fig. R6). Possibly, the expressed TRAIL 
kills only the TRAIL-producing cells diminishing the number of TRAIL-producers and, 
consequently, the level of TRAIL with time. A study by Kim et al. [115] showed that the 
TRAIL gene delivered by an adenoviral vector was substantially more efficient in inducing 
apoptosis when a secretable form of TRAIL was used. Likely, PCI effect on cell death could 
be greatly improved with a plasmid encoding secretable TRAIL, which would allow for 
spreading of the cytotoxic protein and thereby maintenance of the killing effect.  
 
2) The photochemical treatment initiating the PCI-event might also induce pro-survival 
signals. Pro-survival molecules like Heat shock proteins (Hsp), Inhibitor of apoptosis proteins 
(IAP) or the transcription factor NF-κB could be mentioned in that respect (Introduction, 
chapter 2.2.1). These molecules might interfere with apoptosis induced by the PCI-delivered 
TRAIL. It has already been demonstrated that the photochemical treatment as used in this 
study enhances the level of Hsp70 in HCT-116 cells [83]. Hsp are known to inhibit several 
essential steps in the apoptotic process e.g. block apoptosome formation preventing caspase-3 
activation via the intrinsic apoptotic pathway [86, 90]. Additionally, it has been shown by 
microarray analysis that photochemical treatment initiating PCI also up-regulates genes like 
XIAP (inhibiting caspase-3, -7 and -9) and some genes from the NF-kB pathway in WiDr 
colon carcinoma cells (Prasmickaite, unpublished results). Studies have also shown that PDT 
with other photosensitisers than those used in PCI can induce pro-survival signals [116, 117], 
especially when sub-lethal doses of PDT are employed. Based on these data, one could expect 
that such up-regulation might occur also in HCT-116 carcinoma cells, which would imply 
enhanced level of anti-apoptotic molecules following PCI of TRAIL gene. If the 
photochemical stimulation of anti-apoptotic factors counterbalances the PCI-enhanced 
expression of TRAIL, the cytotoxic effect of PCI with pORF-hTRAIL might be lower than 
expected. It should be noted that the similar study by Engesæter et al. (submitted) 
demonstrated that the TRAIL gene delivered by an adenoviral vector with PCI leads to at 
least 100-fold higher levels of the expressed TRAIL protein as compared to the levels 
achieved by PCI of the PEI/pORF-hTRAIL polyplexes. High amounts of TRAIL can induce 
strong apoptotic signals, which could more easily overcome the anti-apoptotic signals and 
therefore lead to synergistic killing, as it was shown by Engesæter et al. Moreover, recently 
Rudner et al [118] proposed a model suggesting that high doses of TRAIL do not require the 
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intrinsic pathway for apoptosis propagation even in type II cells like the HCT-116. However, 
for low doses of TRAIL or weak TRAIL-signal the involvement of the intrinsic pathway is 
crucial. Thus, the apoptosis inhibitors like Hsp70, acting mainly on the intrinsic pathway, 
might have a greater impact when a low level of TRAIL is produced, which seems to be the 
case for PCI of pORF-hTRAIL in the HCT-116 cells. Therefore, combined therapies 
employing PCI of the pro-apoptotic TRAIL gene together with molecular inhibitors (e.g. 
siRNAs) against anti-apoptotic HSPs, IAPs or others might be an interesting approach trying 
to enhance cell death [119].  
 
3) The pORF-hTRAIL plasmid, used in most of the experiments in the present study, delivers 
the TRAIL gene driven by the human Elongation Factor 1α (EF-1α) promoter, which is 
reported to be a strong promoter in most tissues [120]. So far, there are no extensive studies 
on how EF-1α promoter responds to the PCI-relevant photochemical treatment. The recent 
microarray-based study, investigating the effect of the PCI-relevant photochemical treatment 
on various genes/corresponding promoters in WiDr colon carcinoma cells, showed that 
elongation factor genes were neither suppressed, nor stimulated when measured 3 h after the 
photochemical treatment (1.1±0.2-fold up-regulation in respect to “no photochemical 
treatment”, Prasmickaite, unpublished data). This suggests that gene expression driven by 
elongation factor promoters is not repressed by PCI-relevant treatment. Still, there is a 
theoretical possibility that EF-1α might be a weaker promoter in HCT-116 cells, leading to a 
different (e.g. shorter) expression pattern of the TRAIL gene compared to expression of e.g. 
the EGFP gene (fig. R4) driven by the strong CMV promoter. So far, the CMV promoter is 
the most tested and has demonstrated the best results with PCI [11, 83]. Moreover, the recent 
study by Engesæter et al., which clearly showed synergistic cell death after PCI of TRAIL 
carried by adenovirus, used a CMV-controlled TRAIL. Therefore, employment of another 
promoter, e.g. CMV, would be one of the possibilities trying to enhance the cytotoxicity 
mediated by PCI and the TRAIL gene carried by non-viral vectors.  It should be noted that 
CMV-controlled TRAIL was tested in the present work (Results, chapter 2.3) without 
showing a notable improvement (fig. R7). However, in this case the TRAIL gene was fused to 
the EGFP gene, making the plasmid construct rather big and quite different from the CMV-
containing constructs that have been shown to be efficient in PCI.  
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4) The over-expression of DR5 does not sensitise the cells to TRAIL-induced apoptosis. The 
recent study of Wenger et al. [121] reported that cells over-expressing the TRAIL gene might 
become resistant to TRAIL, and that such resistance was due to intracellular retention of the 
receptors. It is, however, not very likely that PCI of TRAIL-containing polyplexes result in 
TRAIL-protein amounts that might induce such retention. As mentioned above, PCI of 
TRAIL-containing adenovirus gave 100-fold more TRAIL-protein as compared to the level 
obtained in this study, and still, the synergistic effect on cell death was demonstrated after 
PCI of TRAIL-adenovirus (Engesæter et al., submitted). This indicates that the 
photochemically enhanced level of the TRAIL protein could hardly mediate negative effects 
on apoptosis via death receptors.  However, the possibility that over-expressed DR5 does not 
necessarily lead to an enhancement of apoptosis via the TRAIL-DR pathway, due to e.g. 
improper localisation and/or function is worth considering.  
Summarising the first part of this study, it was demonstrated that PCI of the pro-
apoptotic TRAIL gene delivered by the non-viral vector PEI increases cell death. However, 
more studies are needed, addressing all the issues mentioned above, to obtain a synergistic 
killing effect of this strategy.  
It was also shown that the PCI-effect on cell death was related to apoptosis. Generally, 
the strong induction of apoptosis as detected by the SubG1 assay (fig. R12) was not reflected 
on Western blots (figs. R17-20). This discrepancy might be due to overestimation of apoptotic 
cell fraction when measuring SubG1 cell fraction and/or due to underestimation of apoptotic 
hallmarks by Western blotting, indicating that the real effect on induction of apoptosis by PCI 
of pORF-hTRAIL might be found somewhere in between.  
A weakness of the SubG1 assay is that it probably also includes cells that are e.g. pre-
necrotic or late-apoptotic. Therefore employment of another assay like cell staining with 
annexin-V (detects loss of membrane asymmetry in apoptotic cells) followed by flow 
cytometric analysis [122] would allow to discriminate between early-apoptotic, late-apoptotic 
and necrotic cells. It can be mentioned that annexin-V staining of photochemically treated 
HCT-116 cells confirmed that necrosis is not a dominant death pathway after PDT with the 
photosensitisers used in PCI (Prasmickaite, unpublished data). However, both early- and late-
apoptotic cells were detected 1-2 days after treatment, though at a lower level than detected 
here by measuring the subG1 cell fraction, indicating that the SubG1 assay might indeed 
over-estimate the apoptotic fraction. 
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Despite the non-conclusive results obtained by Western blotting, the evaluation of the 
molecular apoptosis mechanisms following PCI versus the single treatments, PDT and pORF-
hTRAIL, did lead to some findings.   
Most noteworthy, caspase-8 was activated by PCI, which suggests, as expected, an 
activation of the extrinsic apoptotic pathway by PCI of pORF-hTRAIL. It also seems like the 
extrinsic pathway, involving caspase-8, was activated by PDT alone, which is known to be a 
secondary apoptotic feature of PDT [45]. Caspase-8 appeared to be activated 18 h after 
combined (i.e. PCI) or 24h after individual PDT treatment. This indicates that both PCI and 
PDT induce relatively delayed apoptosis, which was not unexpected. Delayed apoptosis after 
PDT is in agreement with Noodt et al [40], who showed that other lysosomally localised 
photosensitisers induce apoptosis apparent only after >12 hours. One would not expect a rapid 
induction of apoptosis after transfection of pORF-hTRAIL either, as transcription and 
translation steps are required before the TRAIL protein is produced and can induce apoptosis. 
Moreover, there are several indications that photochemical treatment might temporally 
suppress translation, ([11, 123, 124], Prasmickaite, unpublished data), implying that TRAIL 
synthesis might be delayed in PCI-treated cells. Nevertheless, it might seem that PCI leads to 
a bit earlier caspase-8 activation than PDT does (fig. R17). In addition, the activation of 
caspase-8 seems to be prolonged after PCI as compared to PDT, most likely due to 
photochemically internalised and expressed TRAIL protein. The earlier caspase-8 activation 
after PCI might be a result of a stronger apoptotic signal after PCI, when both TRAIL- and 
PDT-treatments are combined, making it easier to detect the active caspase-8. Alternatively, it 
might indicate that caspase-8 is directly activated by photochemically internalised TRAIL, 
while activation of caspase-8 after PDT is a secondary event, and therefore appears later. An 
experimental artefact could also be an explanation, since the 18h-PDT-sample gave an unclear 
band on the particular Western blot (fig. R17).  
The activation of caspase-8 was followed by cleavage of the key death substrate PARP 
(fig. R20), which unfortunately, was quite unpronounced (probably due to detection 
problems) and did not correspond to other data indicating significant apoptosis.  Despite that, 
it can be concluded that only PCI led to detectable PARP cleavage, however, without 
detectable activation of the main executioner caspase, caspase-3. The latter result seems to be 
valid, as an enzymatic assay of caspase-3 activity also showed negligible activation in HCT-
116 (fig. R9). In comparison, other colon carcinoma cells, WiDr, displayed substantially 
activated caspase-3 after both PDT and PCI where PCI induced the highest activation (fig. 
R10). Furthermore, a recent study by Furre et al. [125] also showed induction of apoptosis in 
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HCT-116 cells in a caspase-3 independent manner after photochemical treatment, however, 
with a photosensitiser not relevant for PCI (5-ALA-based PDT). The lack of significant 
caspase-3 activation in HCT-116 cells partially corresponds to the data of Engesæter et al. 
(submitted), demonstrating quite low activation (hardly detectable in Western blots) of 
caspase-3 in HCT-116 following PDT as used in this study. However, Engesæter et al. 
showed clearly detectable active caspase-3 in HCT cells after transduction with TRAIL-
adenovirus with or without PCI. This, again, implies that adenovirus-based delivery of the 
TRAIL gene was much more potent than the non-viral based transfection used in this study.  
All together, studies of caspase-3 activation suggest an alternative apoptotic 
mechanism in HCT-116 as a response to PDT or to PCI of pORF-hTRAIL, possibly involving 
other executioner caspases e.g. caspase-6 and caspase-7 or a combination of caspase-3 and -7, 
where caspase-3 does not play the major role [126]. This remains to be elucidated.  
The role of the intrinsic (mitochondrial) pathway, involving caspase-9, also remains to 
be elucidated. Though there are some indications (reduced level of procaspase-9, fig. R18B) 
that caspase-9 might be activated after PDT and PCI of pORF-hTRAIL, clear activation of 
caspase-9 was not detected (fig. R18B). This was unexpected since, according to the 
literature, PDT generally activates this pathway [45, 127].  Moreover, HCT-116 cells belong 
to the type II cells, in which TRAIL-induced apoptosis requires signal amplification from the 
extrinsic to the intrinsic pathway [73, 75]. Therefore, the fact that active caspase-9 was not 
registered can probably be ascribed to the detection problems that remain to be solved before 
further conclusions can be drawn. An alternative would be to measure other hallmarks of 
apoptosis indicating the involvement of mitochondria e.g. change of the mitochondrial 
membrane potential, release of cytochrome c or detection of Bid/tBid [79, 128, 129]. Another 
possibility, that the mitochondrial pathway was not involved due to e.g. inhibitory effects of 
photochemically induced pro-survival molecules (like Hsp or IAP), has already been 
discussed above and should not be excluded.  
Finally, it can be noted that transfection of pORF-hTRAIL without PCI did not show 
any signs of apoptosis at the molecular level, which generally indicates that this treatment was 
the weakest in inducing cell killing compared to PCI of pORF-hTRAIL and PDT alone, 
corresponding also to the survival data obtained (fig. R6).  
Taken together, the data presented here showed that a pro-apoptotic gene like TRAIL 
combined with the nonviral vector PEI can be delivered into carcinoma cells by the help of 
PCI, and that this leads to both enhanced cytotoxicity and enhanced apoptosis in PCI-treated 
cells. However, further studies are needed in order to obtain a desirable synergistic effect as 
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well as to understand the molecular mechanisms behind cell killing by PCI of the TRAIL 
gene.     
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Future perspectives 
The results presented in this study showed that PCI of the TRAIL gene delivered by a 
nonviral vector is an interesting approach, resulting in higher cytotoxicity in vitro as 
compared to the individual treatments - photochemical treatment (PDT) or non-viral 
transfection with the TRAIL gene.  However, a stronger synergistic effect on cell death is 
necessary before this approach can be suitable for in vivo situations.  
This might be achieved in a number of ways: 
i) Employ a plasmid where the TRAIL gene is controlled by a strong promoter 
known to be induced, or at least not repressed, after PCI treatment.  
ii) A secretable form of the TRAIL gene would be preferential. 
iii) To investigate whether the photochemical treatment induces anti-apoptotic signals. 
In case anti-apoptotic signals are activated, PCI of the pro-apoptotic TRAIL gene 
should be combined with inhibitors of such anti-apoptotic factors. 
Understanding of the PCI effect on pro-survival factors would be valuable not only in 
respect to TRAIL, but also in respect to other molecules delivered by PCI and aimed at 
inducing apoptosis.        
It would also be of interest to continue studies of the molecular mechanisms behind 
PCI of the TRAIL gene, trying to reveal the role of each apoptotic pathway. Many of the 
questions could be answered by the help of a successful Western blotting protocol. The 
establishment of such a protocol requires individual optimisation for each protein to be 
analysed, and for each new antibody employed. In the present study this was solved for a very 
small number of proteins and there is a big room for optimisation.  
 
Experiments employing inhibitors of various caspases would also be interesting in 
order to investigate further the role of different caspases in the induction of apoptosis by PCI 
of a pro-apoptotic gene like TRAIL. 
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Appendix 
1 Buffers for SDS-PAGE and Western Blotting 
1.1  SDS lysis buffer 
Tris-HCl pH 6.8 62.5 mM 
SDS   2 % w/v 
Glycerol  10 % 
DTT   50 mM 
Bromphenol blue 0.01 % 
 
Immediately before lysis, 945 µl of the SDS lysis buffer was supplemented with the 
following: 
Protease inhibitor cocktail  10 µl  
Phospatase inhibitor cocktail I 10 µl   
Phospatase inhibitor cocktail II 10 µl  
PMSF     5 µl  
NaF (1 mM)    5 µl  
Na3VO4     5 µl  
β-Glycerolphosphate (1.5 M) 10 µl 
1.2  RIPA-buffer 
Tris-HCl  50 mM 
Tergitol NP-40 1 % 
Na-deoxycholate  0.25 % 
NaCl   150 mM 
EDTA   1 mM 
 
Immediately before lysis, 967 µl of the RIPA-buffer was supplemented with the following: 
Na3VO4 (1 mM)   5 µl 
Protease inhibitor cocktail  10 µl 
NaF (1 mM)    5 µl 
β-glycerolphosphate (1.5 M)  14 µl 
 
1.3  4x sample buffer 
Tris-HCl, pH 6.8 (1.5 M) 46.6 ml 
Glycerol   40.0 ml 
SDS (30 % w/v)  26.7 ml 
Bromphenol blue (1 %) 4.0 ml 
dH2O     2.7 ml 
1.4  Running buffer (5x) 
Tris-base  15 g 
Glycine 72 g  
Dilution up to 1000 ml with dH2O  
SDS  5 g 
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Before use the buffer was diluted 1:5 in dH2O 
 
1.5  Transfer buffer  
Tris-base 15.1 g 
Glycine 74.1 g 
Methanol 1000 ml 
Dilution up to 5000 ml with dH2O 
SDS   3.75 g 
 
1.6  10x Tris-buffered saline (TBS)  
Tris-base 12.11 g 
NaCl  87.66 g 
Dilution up to 1000 ml with dH2O, pH adjusted to 7.6 
 
1.7  Wash buffer 
10x TBS  100 ml 
Tween20 (10 %) 10 ml 
Dilution up to 1000 ml with dH2O 
 
1.8  Blocking buffer 
Wash buffer   100 ml 
Powdered skimmed milk 5 g 
 
2  Preparation of cell lysates for DR5 analysis using the RIPA-
buffer  
HCT-116 cells were treated as described in Materials and methods, chapter 2.1.2. The cell 
samples were prepared 4, 8, 18 or 24 h after light exposure by the following procedure: 
 
1. The medium containing the floating cells from two parallel wells on a 6-well-plate 
was transferred to a tube. 
2. The adherent cells were detached by trypsinisation and collected into the same tube, 
which was put on ice. 
3. The cells were then pelleted and kept on ice. 
4. Finally the pellet was washed twice in PBS to remove trypsin and FCS before 50 µl of 
complete RIPA buffer was added to the cells. Mixed well with a pipette and let the 
samples stay on ice for about 20 min before they were put in –80oC.. 
 
Upon use the lysates were added 1 µl of benzonase and an O.D. measurement was performed 
to ensure equal loading. An appropriate amount of sample according to these measurements 
was added to 10 µl of 4x sample buffer and applied to the gel. The remaining procedure was 
performed as described in “materials and methods”.  
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